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Department of Neurology 
Rhabdomyosarcoma (RMS) is a pediatric tumor of skeletal muscle that fails to undergo 
terminal differentiation, even though it expresses the myogenic regulatory factor MyoD, 
which should be sufficient for that process. We have previously provided evidence for 
mUltiple inhibitory transcription factors in the tumors acting to oppose the activity ofMyoD. 
Even so, we have found that it is possible to restore MyoD activity by forcing it to interact 
with one of its protein dimer partners, which leads to differentiation of the cells, and 
downregulation of the inhibitors. This work now demonstrates that differentiation ofRMS 
can be achieved by expressing other transcription factors that play positive roles in 
myogenesis, RUNXI and RP58, and that all these mechanisms of differentiation result in the 
increase of a single microRNA, miR-206, that is itself sufficient to differentiate Rl\1S. One 
of the inhibitory factors we previously found as opposing MyoD, MSC, acts at the promoter 
of miR-206 to interfere with the MyoD activity necessary for the microRNA's expression. 
Other analyses of expression and gene regulation suggest the existence of an epistatic 
relationship between MyoD, RUNXI, RP58, and miR-206, with MyoD positively regulating 
all the other targets, RUNXI assisting with the activation of RP58 and miR-206, and miR-
206 the target of all the other factors. Genome-wide analysis of DNA binding by MyoD and 
MSC demonstrates that both factors bind throughout the genome of RMS, with both distinct 
and overlapping binding. Comparison of MyoD binding in Rl\1S to that of MyoD in primary 
human cells reveals differences in the binding sites for possible cooperative factors, 
including RUNXl, but an overall similarity in the MyoD binding between IL\lIS and human 
myotubes. Taken as a whole, the data suggests that RMS represent an arrested state of 
development balanced between myoblast and myotube, and that manipulation of components 
ofthe myogenic gene program can 'tip the balance' and restore their ability to differentiate. 
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Chapter 1: Introduction 
This chapter should be considered in the context of the following publications, and Figure 1.1 
has been reproduced from the third publication: 
Cao, Y., Yao, Z., Sarkar, D., Lawrence, M., Sanchez, GJ., Parker, M.ll, MacQuarrie, K.L., 
Davison, I, Morgan, M.T., Ruzzo, W.L., Gentleman, RoC., and Tapscott, SJ. (2010) 
Genome-wide MyoD binding skeletal muscle cells: a potential for broad cellular 
reprogramming. Dev. Cell 18(4), 662-674. 
Yang, Z., MacQuarrie, KL., Analau, Tyler, A.E., Dilworth, FJ., Cao, Y., Diede, S.l, 
and Tapscott, SJ. (2009) MyoD and E-protein heterodimers switch rhabdomyosarcoma cells 
from an arrested myoblast phase to a differentiated state. Genes Dev. 23(6), 694-707. 
MacQuarrie, K.L. and Tapscott, SJ. (2011) Stuck in a Balancing Act: Histone 
Methyltransferase Activity ofKMTlA Traps Alveolar Rhabdomyosarcomas in an 
Undifferentiated State. Cell Cycle, 10(19). 
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Skeletal Muscle Development 
Development in the embryo 
The process of skeletal muscle development in vertebrates begins in the embryo, and 
must shepherd cells through processes of lineage commitment, terminal differentiation, and 
tissue maturation, to make a functional muscle. While some variability has been described in 
earlier steps of the process, as described below, ultimately skeletal muscle development 
converges at the level of giving rise to a population cells that express the myogenic 
regulatory factors (MRFs). Though few in number, the MRFs are remarkable in their role as 
the transcription factors that serve to regulate the gene networks that control skeletal muscle 
fate, structure and function. 
The majority ofthe cells that will become skeletal muscle originate in the somites, 
structures that lie laterally to the neural tube and notochord and give rise to numerous cell 
types. Somites produce not only the myogenic cells, but those of dermal, skeletal and 
cartilaginous lineages as well (Mok and Sweetman, 2011). The majority of the myogenic 
cells in developed tissues come from the somites, though there are some exceptions. Somites 
serves as the point of origin for all skeletal muscles of the limbs and the trunk, but certain 
muscles of the head and neck come from myogenic cells that originate at non-somitic 
locations. Regardless of the point of origin, all cells that give rise to skeletal muscle are 
mesodermal in nature. Somites bud off from the pre-somitic mesoderm as mesenchymal 
cores surrounded by epithelial coverings, and develop sequentially in an anterior-posterior 
fashion. Somites that are located more anteriorly are therefore more developed than the 
somites farther in the posterior direction at the same timepoint. 
Somites divide into sub-struetures over time, with the first dorsal-ventral division 
resulting in the ventrally located sclerotome, originator of the axial skeleton, and the dorsally 
located dermomyotome. The dermomyotome, as its name suggests, includes a mixture of 
both dermal and myogenic precursor cells, and is the first point when myogenic precursors 
can be detected. Further development results in the delamination of cells from the lips of the 
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dennomyotome, the migration of those cells ventrally, and establishment of the myotome. 
The myotome is further divided into the epaxial and hypaxial myotomes, which receive 
migrating cells from different areas of the dermomyotome and eventually go on to give rise 
to different muscles (Ordahl and Le Douarin, 1992). The epaxial myotome gives rise to 
more medial muscles, specifically a subset of the muscles of the back, while the hypaxial 
myotome goes on to form muscles of the limbs and body wall. It has also been detennined 
that a second wave of migration of cells into the myotome occurs, resulting in the creation of 
the satellite cell population, which serve as the pool of muscle stem-like cells in the adult 
(Gros et aI., 2005; Lepper and Fan, 2010; Relaix et aI., 2005). 
Though complex in the details, and showing variability in effect between epaxial and 
hypaxial cells, numerous signaling pathways impact on the process of specifying cells to 
become skeletal muscle. Bone morphogenetic protein (BMP) signaling has been identified 
as a negative regulator of myogenesis, and BMP signaling in the dorsal somite is inhibited by 
noggin (Hirsinger et a1., 1997; Marcelle et aI., 1997; Reshefet a1., 1998). The Notch 
pathway has also been shown to be an inhibitor of myogenesis, both in vivo and in vitro 
(Kopan et aI., 1994). Components of the Wnt pathway have been shown to have a positive 
role in the acquisition of myogenesis, with Wnts 1, 3a, and 4 being identified as specific 
positive regulators (Wagner et aI., 2000), and the diffusible Wnt receptors Frzb and Sfrp2 
possibly titrating and modulating their effects (Ladher et a1., 2000). Similarly, sonic 
hedgehog (Shh) signaling has been implicated in having a positive myogenic role, but 
myogenesis in Shh-null mice is specifically compromised in the epaxial myotome, 
suggesting the possibility of a more region-specific effect (Borycki et a1., 1999). 
Transcriptional regulation of skeletal muscle development and the myogenic regulatory 
factors 
While the myogenic cells of non-somitic origin can be specified by factors such as 
Pitx2 (Dong et aI., 2006; Shih et aI., 2007), the myogenic precursor cells that arise from the 
somite are characterized by the expression of the paired box transcription factors Pax3 and 
Pax7 (Gros et aI., 2005; Relaix et a1., 2005). Mice that lack PAX3 do not develop limb 
muscles (Goulding et a1., 1994), and the myogenic defects are even more severe in 
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Pax31Pax7 double knock-out mice (Relaix et al., 2005). The Pax genes have been shown to 
playa role in the survival of myogenic cells before they undergo differentiation (Collins et 
aL, 2009), and are upstream, controlling factors in the expression of the myogenic regulatory 
factors (Bajard et al., 2006; Maroto et al., 1997; Sato et al., 2010). Pax-expressing cells from 
the somites also serve as an important SOUTce of myogenic precursors in developed muscles 
(Gros et al., 2005; Schienda et al., 2006) further demonstrating the crucial role that Pax genes 
play in the development of skeletal muscle. 
The MRFs consist of fOUT related basic helix-loop-helix (bHLH) Class II transcription 
factors that are capable of homo- or heterodimerization through their HLH domain and DNA 
binding through their basic region. MyoD was the first MRF identified, discovered through a 
cDNA subtractive screen (Davis et al., 1987), and the other three MRFs (Myf5, Myog, and 
MRF4) were identified soon thereafter (Braun et al., 1990; Braun et al., 1989; Miner and 
Wold, 1990; Rhodes and Konieczny, 1989; Wright et al., 1989). Extensive work both in 
vitro and in vivo has identified overlapping but distinct activities and roles for the four 
factors. Myf5 and MyoD are known to control the process of commitment to the myogenic 
lineage, Myog is a key regulator of terminal differentiation, and MRF4 exhibits a complicated 
role that is involved both in the earlier commitment functions and in differentiation. 
All skeletal muscle cells are characterized by the expression of the MRFs, regardless 
of their location of origin and dependency, or lack thereof, on the Pax genes. The timing of 
expression of the MRFs in miee relates to their described roles and activities - Myf5 is 
expressed and present before MyoD, with both expressed prior to detectable Myog 
expression. MRF4 expression shows a biphasic pattern, with expression in the mouse 
embryo first detectable shortly after the onset of Myf5 expression (embryonic day 9.0), 
followed by a decrease 2.5 days later and then an increase again at day 16.0 (Bober et al., 
1991; Hinterberger et aL, 1991). 
Individual deletions of the Myf5 and MyoD genes result in relatively normal 
appearance of muscle in adult mice, suggesting considerable redundaney between the two 
factors. However, there are observable defects in Myf5 and MyoD knockout myogenic cells 
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of epaxial and hypaxial origin, respectively, demonstrating the ability ofMRFs to substitute 
for each other to a certain extent, while still possessing unique roles (Kablar et al., 1998). 
The phenotype of Myf51MyoD double knock-out mice is one of a complete lack of myogenic 
cells, demonstrating the necessity of these MRFs for the process of determination of the 
myogenic lineage (Rudnicki et al., 1993). Detailed study of the role of Myf5 has been 
complicated by the fact that it possesses regulatory clements dispersed across more than 100 
kb of DNA upstream of its transcription stmt site that is interspersed with the regulatory 
elements of both MRF4 and another gene, but its role in commitment and determination is 
clear (Carvajal et al., 2001; Olson et al., 1996). Both MyoD and Myf5 have been described as 
being nodal points in the process of myogenesis, integrating multiple signals to result in a 
decision about the mutually exclusive processes ofproliferation versus differentiation 
(Weintraub et al., 1991). 
Mice that lack Myog exhibit cells that are committed to the myogenic lineage, but ml 
absence of differentiated cells. This phenotype demonstrates the necessity of Myog for the 
proccss of terminal differentiation, a role that agrees with its expression pattern -later in 
time compared to MyoD and Myf5 (Hasty et al., 1993; Nabeshima et al., 1993). As with 
MyoD and Myf5, Myog also possesses functions that cannot be replicated by the other MRFs; 
MyoD is incapable of substituting for Myog in the process of generating differentiated 
myogenic cells from murine embryonic stem cells (Myer et al., 2001). Conversely, Myog 
cmIDot completely substitute for the role of the earlier MRFs; expression of Myog under the 
control of the Myf5 regulatory elements in Myf51MyoD double knock-out mice was not able 
to completely rescue the double knock-out phenotype (Wang and Jaenisch, 1997). 
The details of the role of MRF4 in differentiation and commitment are significantly 
less clear. Its expression pattern in mouse would suggest roles in both early and later muscle 
processes, but the complicated nature of its regulatory elements has made detailed 
understanding of its role difficult. From experiments that have shown an ability of MRF4 to 
compensate for Myog in murine ES cells (Sumariwalla and Klein, 2001) as well as the 
presence of skeletal muscle in MyoDIMyf5 double-null mice that have preserved MRF4 
function (Kassar-Duchossoy et al., 2004), it can be concluded that MRF4 does have roles in 
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both the processes of determination and differentiation, though its role in the context of the 
other MRFs is still unclear. 
MyoD and the control of myogenesis 
Background on MyoD function in myogenesis 
lv.fyoD was the first myogenic regulatory factor to be identified and for reasons 
ranging from its simpler promoter structure compared to Myf5 and MRF4, to its role as a 
direct regulator of Myog expression, to its ability to drive the entire process of myogenic 
terminal differentiation, it continues to serve as the exemplar of the MRFs. MyoD has been 
termed a 'master regulator' for its ability to turn cells of a non-myogenic origin into 
differentiated myotubes. In the nearly two decades since its identification, much has been 
determined of the molecular mechanisms of both how MyoD affects both cells on a global 
level and how it affects individual gene targets. 
Heterodimers ofMyoD and one of the E-proteins (E2A, HEB, E2-2) are understood 
to be the functional form of MyoD in a cell. While the relative abundance of such 
heterodimers and their preference for specific sequence contexts are still unclear, bHLH 
proteins are known to bind the sequences termed 'E-boxes' (CANNTG). MyoD:E 
heterodimers function as transactivators, meaning that after binding to DNA, they lead to the 
increased expression of their gene targets (Lassar et al., 1991). Experiments have provided 
evidence that the presenee and oceupancy of multiple E-boxes at a given regulatory area 
results in greater stability of binding and enhanced target activation (Gilmour et al., 1991; 
Piette et al., 1990; Weintraub et al., 1990; Wentworth et al., 1991). 
The introduction of MyoD into a cell results in differential expression of hundreds of 
genes in distinct temporal clusters, some increasing in expression, and others decreasing, 
suggesting the action of indirect mechanisms (Bergstrom et al., 2002). The process of 
myogenesis requires temporal control of target expression, as cells are first committed but 
continue to proliferate, and then later shift to differentiation and cell-cycle withdrawal. 
While organogenesis models in simpler systems and organisms, such as the C. elegans 
pharynx, have shown evidence of temporal regulation through the relative afflnity of factors 
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for specific DNA sequences (Gaudet and Mango, 2002), MyoD been shown to control 
through a complex feed-forward regulation of its targets. After induction of its earlier 
gene targets, sueh as p38 MAPK or the Mej2 protein family members, those targets cooperate 
with 1~yoD at the regulatory elements of later genes to activate them, ensuring that, even 
though MyoD ean bind widely throughout the genome, its targets are activated in a regulated 
fashion (Penn et aL, 2004). 
A more recently described role for MyoD in affecting myogenesis has been that of 
microRNA (miRNA) expression. miRNAs are small (~21 nt) non-coding RNAs that bind to 
target mRNAs and mediate downregulation of their targets (Ge and Chen, 2011). miRNAs 
that affect myogenesis, both positively (the mir-1/-206 family), and negatively (the miR-133 
family), have been identified and found to be induced by the action ofMyoD (Kim et aL, 
2006; Rao et aL, 2006; Rosenberg et aL, 2006). While a selection of direct targets have been 
identified for both types of miRNAs and offers some explanation of how they can impact the 
process ofmyogenesis for instance, miR-206 directly targets the p180 subunit of DNA 
polymerase alpha, a component of cellular machinery that would clearly be unnecessary in 
terminally differentiated cells (Kim et aL, 2006) - there are likely numerous, as of yet 
unknown, additional targets. 
Proteins can affect MyoD function positively and negatively 
Numerous proteins have been implicated as co-factors in some capacity for MyoD 
during the process of my ogene sis. Apart from the aforementioned p38 MAPK and Mef 
proteins, roles have also been described for the Hox protein co-factors Pbx and Meis (Berkes 
et aL, 2004), the Six proteins (Spitz et aL, 1998), and the ubiquitous SpJ factor (Biesiada et 
aL, 1999). The exact manner by which such factors cooperate with MyoD vary, but both 
Pbx/Meis and the Six proteins Six1 and Six4 have been shown to impact on the ability of 
MyoD to activate myogenin. The role of the members of the Mej2 family has been described 
more broadly; they appear to act by synergistically cooperating with MyoD at regulatory 
elements (Molkentin et aL, 1995). Adding support to this model is the finding that ,-,-c.'v",'_" 
and Met2 binding sites are closely positioned at many muscle-specific genes (Wasserman 
and Fiekett, 1998). 
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In addition to being positively regulated by cooperating transcription factors, MyoD 
activity can be impaired by diverse factors. One of the most classic family of such factors, 
functional details of which have been known for a few decades, are the ld proteins. There 
are mUltiple Id genes, and they all share the common characteristic of possessing the HLH 
domain necessary for factor dimerization and lacking the basic region that confers DNA 
binding. The model for their function is that they dimerize with factors such as MyoD and/or 
E-proteins, fail to bind to DNA, and therefore functionally disrupt functional protein 
heterodimers by titrating away their component parts (Benezra et al., 1990). It has been 
demonstrated that forcing heterodimerization between MyoD and an E-protein, E47, 
diminishes the inhibitory action oflds, offering further support for the idea that the Ids 
function at the level of dimerization interference (Neuhold and Wold, 1993). 
Other protein factors have also been shown to play various inhibitory roles during 
myogenesis, many of them, though not all, belonging to the bHLH family themselves. The 
bHLH protein Musculin (MSC), also known as MyoR, is expressed in proliferating 
myoblasts and decreases during differentiation both in vitro and in vivo. MSC 
heterodimerizes with E-proteins and binds to E-boxes, and inhibits the process of myogenesis 
when co-expressed with MyoD in fibroblasts (Lu et al., 1999). The bHLH Mistl operates in 
a similar fashion, forming Mistl :MyoD heterodimers that lack activating potential, and 
occupying certain E-boxes as Mistl :Mistl homodimcrs, presumably blockading them from 
functional MyoD occupancy (Lemercier et al., 1998). Decl is another bHLH protein that 
acts by occupying E-boxes as a homodimer and mediating transcriptional repression at bound 
sites (St-Pierre et al., 2002). The bHLH protein Twist titrates away E-proteins and interferes 
with myogenesis both at the level ofMyoD and the Mef2 proteins (Spicer et al., 1996), but 
also has the unusual property of interfering with MyoD and myogenic activity in a protein-
protein interaction that is mediated through the basic region ofMyoD, rather than the HLH 
region (Hamamori et al., 1997). Though not belonging to the bHLH family, Mdfi is strongly 
expressed in the sclerotome during development and sequesters MRFs in the cytoplasm of 
cells when co-expressed, preventing their activity (Chen et al., 1996). Mdfi also affects 
9 
Tc£lLef protein binding, suggesting an additional role in regulation ofWnt signaling and the 
ability to affect myogenesis through that action (Snider et aL, 2001). 
MyoD and chromatin remodeling 
MyoD is capable of mediating significant chromatin remodeling at locations at which 
it binds. MyoD has extensively described interactions with two different histone 
acetyltransferases (HATs): p300 and p300lCBP-associated factor (PCAF). p300 and MyoD 
directly interact, and PCAF is then subsequently recruited to the complex in a p300 
dependent manner, with each of the HATs responsible for a unique role in the process of 
acetylation (Puri et al., 1997 a; Puri et al., 1997b; Sartorelli et al., 1997; Sartorelli et al., 
1999). p300 acts to hyperacetylate residues in the tails of core histone members H3 and H4, 
while PCAF acts to acetylate MyoD itself on two residues located near the basic region. In 
the context of chromatin, in vitro assays have shown that both hyperacetylation events are 
necessary for strong transactivation (Dilworth et al., 2004). 
Evidence from mUltiple MyoD-regulated gene targets - Myog, muscle-specific 
creatine kinase (ckm) and MyoD itself - have shown that prior to the action ofMyoD, the 
DNA at those genomic locations is inaccessible as judged by nuclease accessibility assays, 
indicating a closed or restrictive chromatin structure. In response to ::vlyoD, even in the 
presence of the protein synthesis inhibitor cycloheximide, accessibility increases, indicating 
that chromatin remodeling has taken place (Gerber et al., 1997). Recently, we have shown 
that the histone hyperacetylation that occurs in response to ::vlyoD action is global in natnre, 
and occurs throughout the genome at locales bound by MyoD, even those that are located 
distant to any known transcriptional target (Cao et al., 2010). 
MyoD has also been shown to recruit the chromatin-remodeling SWI/SNF complex, a 
complex comprised of enzymes that perfonn ATP-dependent remodeling of chromatin and 
play roles in gene expression, development, cell fate decision, and cancer (reviewed 
in(Hargreaves and Crabtree, 2011). In the case of myogenic cells, the MyoD recruitment of 
SWI/SNF occurs through mechanisms that are dependent on p38 signaling (Simone et al., 
2004). SWI/SNF complexes recruited at the Myog locus are done so after histone acetylation 
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has taken place, but actually prior to stable MyoD binding (de la Serna et aI., 2005). Pbx has 
been shown to bind constitutively in that area, suggesting that Pbx interaction with MyoD 
pennits first histone acetylation, than SWVSNF activity, and finally stable MyoD occupancy 
(Berkes et al., 2004), suggesting a specific model for how MyoD, chromatin remodeling 
complexes, and myogenic co-factors can interact to regulate target expression. Interestingly, 
SWIISNF activity is still required in developed cells for expression of myogenic genes, 
emphasizing the importance of chromatin remodeling in myogenesis (Ohkawa et al., 2007). 
Other evidence has also identified negative regulators of chromatin accessibility as 
associating with MyoD and affecting its function. The histone methyltransferase KMTlA is 
responsible for methylation of histone 3, lysine 9 (H3K9), a histone tail modification 
associated with gene silencing. In myoblasts, KMTlA has been shown to associate with 
MyoD at the myogenin locus, and then decrease both in occupancy and protein level as 
myogenic differentiation occurs (Mal, 2006). Similarly, histone deacetylase 1 (HDACl) has 
been implicated in preventing MyoD action prior to tenninal differentiation. Biochemical 
evidence showed an association between MyoD and HDAC1 in myoblasts, suggesting that 
HDACI could be utilizing MyoD to target areas of the genome to deacetylate and thus render 
silent, preventing premature gene activation. During the process of differentiation to 
myotubes, hypophosphorylation of the retinoblastoma protein (pRb) leads to an increased 
association between pRb and HDAC1 and a concomitant decrease in the MyoD:HDACl 
association (Puri et al., 2001). Together, these data suggest a model in which MyoD 
associates in undifferentiated myoblasts with chromatin remodelers that function as silencers 
or repressors and lead to less accessible structures. myogenic cells differentiate, MyoD 
thcn transitions away from this association. The experiments demonstrating a relationship 
betwecn MyoD and negative chromatin regulators have been done on single targets and 
through biochemical approaches, and so it is still unclear at this time how generalizable these 
findings are across the genome. 
Reccnt work from our lab, bricfly mentioned above in the context of global histone 
acetylation in response to MyoD binding, has utilized the tcchnique of chromatin 
immunoprecipitation coupled to high-throughput sequencing (ChIP-Seq) to identify MyoD 
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binding at tens of thousands of sites throughout the mammalian genome, even at very high 
levels of statistical stringency (Cao et al., 2010). Motif analysis of DNA located adjacent to 
locations bound by MyoD identified potential binding sites for well-described (eg. Meis, 
API, SP1) and less characterized (Runx1) co-factors, as well as motifs for DNA-binding 
factors that may themselves be interfering with MyoD binding (eg. RP58). The unexpected 
finding that MyoD binds at a multiplicity of sites remote to any gene target raises many 
questions however. One of the more obvious is how and why MyoD 'chooses' binding sites, 
given 1) that there are many more potential binding sites (E-boxes) in the genome than actual 
sites of MyoD binding, and 2) there are many more MyoD bound sites than direct gene 
targets. While answers to these issues are still elusive, possible explanations for these 
observations are addressed conceptually in Chapter 4. 
Rhabdomyosarcoma 
Background on rhabdomyosarcoma 
Rhabdomyosarcoma (RMS) is a soft tissue sarcoma of skeletal muscle that arises 
mainly in pediatric populations, and is characterized by expression of myogenic regulatory 
factors, especially MyoD, and varying amounts of other skeletal muscle genes (Merlino and 
Helman, 1999; Merlino and Khanna, 2007; Sebire and Malone, 2003; Xia et al., 2002). 
Despite the expression of one or more MRFs, all RMS fail to terminally differentiate, and 
therefore continue their inappropriate growth. RMS ranks as the most common of all soft 
tissue sarcomas in children, accounting for one-half of all such cases, and approximately 5% 
of all cancers in children. Approximately 350 new cases are diagnosed in the US each year. 
Current overall survival rates are reported as approximately 70%, but prognosis is strongly 
dependent on tumor location (for review, see (Paulino and Okcu, 2008). 
Rhabdomyosarcomas are grouped into three major subclasses - alveolar (ARMS), 
embryonal (ERMS), and pleomorphic. Further distinctions have been made among the 
subtypes themselves (eg, botryoid is a further subclass of embryonal), but classification on 
the level of the three major subtypes reveals substantial differences between them. 
Embryonal RMS is the most COlmnon subtype found in pediatric populations, making up 
two-thirds or more of all cases. ERMS also tends to appear in younger popUlations, with 
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tumors often located in the retroperitoneal, genitourinary, and orbital areas. Alveolar tumors 
comprise the bulk of the remainder of diagnosed RMS, often appearing in an older patient 
population than ERMS. ARMS exhibits differences in the areas it tends to affect, and is 
more likely to be found in the limbs in comparison to ERMS. Pleomorphic tumors hold the 
unusual distinction of appearing mainly in adult populations and, unsurprisingly, make up a 
very small proportion of all diagnosed RMS. Those few pediatric patients that are diagnosed 
as having disease with pleomorphic characteristics often have tumors of mixed embryonal-
pleomorphic qualities (Newton et aL, 1988). 
As mentioned above, all rhabdomyosarcomas share the characteristic of a failure to 
undergo myogenic differentiation appropriately, preventing their terminal withdrawal from 
the cell cycle, and guaranteeing their continued proliferation. The majority of diagnosed 
ARMS share one of two chromosomal trans locations - an aberrant joining of chromosome 
13 with either chromosome 1 or 2 (t(1;13)(p36;q14) and t(2;13)(q35;q14), respectively). 
This translocation results in a fusion between the F'KHR (FOX01A) gene, a member of the 
family of fork head transcription factors, and either PAX3 or PAX7 (Barr et al., 1993; 
Buckingham, 2007; Davis et aL, 1994). The newly formed PAX-FKHR fusion gene 
possesses the DNA binding characteristics of PAX, but transcriptional activity up to 100 
times as strong as that of non-fusion PAX (Fredericks et al., 1995). Studies comparing 
PAX3-FKHR and PAX3 demonstrated that the fusion protein is more capable of repressing 
myogenic differentiation in cultured cells than the wild-type protein (Epstein et al., 1995), 
and therefore is hypothesized to contribute heavily to the pathogenesis of ARMS. 
In contrast to the situation with ARMS, ERMS have never been identified as 
possessing a characteristic chromosomal rearrangement that could help explain their evasion 
of terminal myogenic differentiation. An area on the small arm of chromosome 11 (11 P 15) 
has been identified as a region that often undergoes allelic loss in the tumors (Koufos et al., 
1985), but chromosomal transfer experiments suggest that the chromosomal region contains a 
tumor suppressor, not a regulator of my ogene sis (Koi et al., 1993). Indeed, none of the 
identified gene products from the region playa skeletal muscle specific role, but instead 
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include such products as the cyclin dependent kinase inhibitor p571Kip2 (reviewed in (Xia et 
al.,2002). 
Transcription factors, microRNAs, and chromatin remodelers can affect RMS 
proliferation and differentiation 
It has been demonstrated that various cellular pathways function in the maintenance 
of the undifferentiated state of both alveolar and embryonal ~\1S. Pathways that have been 
implicated in the block of differentiation include that ofp38 MAP kinase (Puri et al., 2000), 
the myogenic regulatory factor MRF4 (Sirri et al., 2003), a NF-KBNY-lImiR-29b circuit 
(Wang et al., 2008), RAS (Langenau et al., 2007), c-MET and the INK4a/ARF locus (Sharp 
et al., 2002), myostatin (Rossi et a1., 20 II) and insulin-like growth factor 2 (Hahn et al., 
2000). No common link has been demonstrated between these pathways however, making it 
unlikely to be able to purposefully develop any single curative therapy, and obscuring any 
common molecular origins of the tumor. 
More recently, the bHLH factor HESl (hairy enhancer of split 1) was found to playa 
role in the differentiation block in RMS. Work at the Fred Hutchinson identified HESl as 
playing a key role in preventing cells from permanently withdrawing from the cell cycle - an 
event that occurs both in cellular senescence and in differentiation. Specifically, HES 1 
activity was necessary to keep cells competent to re-enter the cell cycle; abrogation of HES 1 
activity led to an inappropriate and permanent exit from the cycle. Since RMS themselves 
are a cell type that fails to permanently exit the cell cycle when it is appropriate for them to 
do so, a dominant negative HES 1 was introduced into a cell culture model and found to lead 
to restoration of appropriate myogenic differentiation in the cells tested (Sang et al., 2008). 
Apart from the impact on RMS models, HES 1 is of special interest since it has been 
described as functioning as an inhibitor of MyoD nmction; it ch'amatically decreases MyoD 
activity on myogenic reporters when co-expressed with MyoD and E-proteins. HES 1 RNA 
is found at high levels in undifferentiated skeletal muscle and then is drastically decreased in 
level in mature skeletal muscle (Sasai et al., 1992). 
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Work in cell culture models of ARMS has identified KMTlA, the histone 
methyltransferase found to associate with MyoD in myoblasts, as being aberrantly regulated 
in RMS cells. When cells were shifted to culture conditions that would induce differentiation 
in normal myogenic cells -low-serum media they actually upregulated KMTlA, and its 
methyltransferase activity was found to increase, not only generally, but at its known MRF 
target Myog. shRNA-mediated knockdown of KMTI A led to a differentiated cellular 
phenotype, increase in markers of myogenesis and, most strikingly, reduced tumor formation 
in xenograft mice models (Lee et al., 2011). This study offers an interesting contrast to the 
results with HESl, demonstrating that differentiation in RMS could be achieved not only 
through the actions of transcription factors, but the chromatin factors associated with them. 
Other recent work has shown the impact of additional members of the myogenic 
network on the biology ofRMS. Multiple groups have shown that the microRNA miR-206 
is underrepresented in RL\1S, and that increasing its levels in tumors, both in vitro and in vivo, 
lead to differentiation of the cells (Missiaglia et aI., 2010; Rao et al., 2010; Tau1li et aI., 
2009). In the case of xenograft mouse models of RMS, the increase in miR-206 expression, 
induced by injections of a miR-206 expressing lentivirus, even led to reduced tumor growth 
while the injections continued. Taken as a whole, the data from individual players in the 
myogenic network, whether they are transcription factors, chromatin remodelers, or small 
RNAs, suggest that not only is the process of myogenesis impaired in RMS, but that 
manipUlation of my ogene sis is both possible and desirable from the perspective of treatment. 
A model of rhabdomyosarcoma as trapped at a 'tipping point' in the myogenic process 
Initial work from our lab demonstrated that MyoD target activation was compromised 
in RMS, while MyoD itself exhibited no defects. Specifically, MyoD showed low activity in 
measures of transcriptional activity on myogenic reporters in RMS cell culture systems, but 
chimeric proteins made up of the DNA binding region of a Gal protein and MyoD activated 
targets many times more strongly. Further, formation ofheterokaryons between RMS cell 
lines and normal fibroblasts led to a rescue of MyoD activity and a restoration of the ability 
of RMS to differentiate into skeletal muscle (Tapscott et aI., 1993). Taken as a whole, this 
work suggests two non-exclusive possibilities - that ~MS 1) lack a necessary activating 
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factor that is not skeletal muscle or myoblast specific and is provided by the fibroblasts, 
and/or 2) lack one or more inhibitors that themselves function to downregulate or antagonize 
myogenic inhibitors in RMS. It is also noteworthy that heterokaryon fusion between RMS 
cells, even those of different subtypes, failed to rescue differentiation, suggesting some sort 
of common thread between cell types. 
Tying in with this identification of the role of a myogenic bHLH inhibitor 
contributing to the state ofRMS, we have recently expanded the initial work on 
compromised MyoD activity in RMS. We have identified multiple other bHLH myogenic 
inhibitors as being present in RD cells, a cell culture model of the embryonal subtype 
(McAllister et al., 1969), and contributing to the block in MyoD-mediated differentiation. 
We identified both MSC, a factor previously mentioned in the section on MyoD and 
myogenesis, as well as a previously uncharacterized splice form ofE2A, one of the E-
proteins, that we termed E2A-2/5. Both factors act in a repressive manner on MyoD activity 
in RD cells and, in the case of MSC, compete with MyoD for a limiting quantity of E-
proteins to serve as a heterodimerization partner (Yang et al., 2009). When considered with 
the results from 1 and KMTlA studies mentioned above, this suggests a model for 
the molecular mechanisms that keep RMS trapped in a proliferative state. 
Specifically, the data suggests that RMS are balanced between the states of 
proliferation and differentiation (Figure 1.1). They possess both MyoD and E-proteins, 
which should act to drive differentiation, but also possess a variety of inhibitory factors that 
include, but are not limited to, MSC, E2A-2/5, HESl, and KMTlA. This balance, rather 
than representing a tumor-specific state, is reminiscent of a state found during normal 
development. In normal cells, this balance between inhibition and activation serves to 
suspend MyoD activity until the point at which the cells have filled a sufficient anatomic 
spaee and can eoordinately differentiate. In RMS, this balance is inappropriately maintained 
and permits the eells to continue to proliferate. When the balanee is disrupted, sueh as by 
downregulating or interfering with the negative factors, or inereasing the positive factors, 
differentiation is favored and proceeds. 
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Offering further support for our model, we have demonstrated that forced protein 
heterodimers of MyoD and the E-protein E12 differentiate RD cells when introduced 
retrovirally (Yang et aI., 2009). As would be expected, the cells shifted to the differentiated 
myotube morphology, up regulated myogenic markers, and withdrew from the cell cycle. 
Further, in agreement with the predictions of our model, they also coordinately 
downregulated the levels of numerous myogenic inhibitors. E2A-2/5 decreased at the RNA 
level, MSC was found to decrease at the protein level, and both Mdfi and Dec1 were found 
by expression array analysis and subsequent confirmatory RT-PCR to decrease. This 
suggests that the effect of the MyoD~E12 forced dimer is not simply to overwhelm the 
inhibitory factors that exist in Rc\t1S, but to restore the normal process of myogenesis in 
which inhibitory factors are downregulated as the process occurs. This results in a negative 
feedback loop that ensures that the activity of MyoD will proceed without interference and 
lock in the differentiated state. 
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Figure 1.1. 'Tipping point' model of switch from proliferating myoblasts to 
differentiated myotubes in normal development and rhabdomyosarcoma. (Top) In 
normal, proliferating myob1asts, as well as the skeletal muscle tumor rhabdomyosarcoma, a 
competition exists between the activating factors MyoD and its E-protein dimerization 
partner and inhibitory complexes in which MyoD:E is associated with KMTlA. Numerous 
other inhibitory factors exist as well, resulting in the prevention of competent myogenic 
target activation and the cell being trapped in an undifferentiated state. (Bottom) Upon a 
shift in the balance of the factors such that activation predominates, myogenic targets act 
negatively upon the inhibitory factors and complexes and thereby perpetuate their own 
expression, ensuring that the process of differentiation will go to completion. 
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Chapter 2: Diverse means to differentiate rhahdomyosarcoma cells function through a 
single myogenic microRNA 
19 
Summary 
The pediatric tumor of skeletal muscle, rhabdomyosarcoma (RMS), expresses the 
myogenic bHLH protein MyoD a factor that should be sufficient to eause the cells to 
differentiate - but continues to proliferate. Restoration of myogenic activity in RMS by 
cxpression of a forced protein dimer comprised of MyoD and a dimer partner E-protein 
results in differentiation of the eells, and the downregulation of numerous transcriptional 
inhibitors of myogenesis present in the RMS eells. We now show that the action of the 
forced dimer increases the expression of two other transcription faetors, RUNX1 and RP58, 
that are themselves sufficient to differentiate RMS cells when expressed in them, and that all 
of the pro-differentiation factors lead to an inerease in the levels of the microRNA miR-206. 
RUNX1 appears to act to activate RP58 and miR-206 in conjunction with MyoD, suggesting 
an epistatic relationship between the factors. Further, the inhibitory bHLH protein MSC 
appears to eompete with MyoD at the miR-206 promoter to prevent its strong activation by 
occluding a DNA binding site needed by MyoD. Together, the data suggests that multiple 
factors that can differentiate RMS cells function through miR-206, and its activity is 
regulated by a competition between bHLII factors and their DNA occupancy. 
Introduction 
Rhabdomyosarcoma (RMS) is a soft tissue sarcoma of skeletal muscle that arises 
mainly in pediatric populations, and is eharacterized by expression of myogenic regulatory 
factors (MRFs), especially MyoD, and varying amounts of other skeletal muscle genes 
(Merlino and Khanna, 2007; Sebire and Malone, 2003; Xia et a1., 2002). MyoD is a basic 
helix-loop-helix (bHLH) transcription factor that serves as a transcriptional activator when 
bound to E-box sequences (CANNTG) in a heterodimer with one of the ubiquitous E-
proteins (HEB, E2-2, or E2A) (Lassar et al., 1991). MyoD aets in a promoter-specific 
manner to regulate its targets, and is responsible for both aetivating targets directly, as well 
as leading to downregulation of a subset of genes (Bergstrom et al., 2002). 
MyoD is capable of converting multiple cell types into terminally differentiated 
skeletal muscle when expressed (Davis et al., 1987), and is capable of positively regulating 
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the expression of the MRFs Myog (Cao et a1., 2006) and JVRF4 (Black et a1., 1995). The 
process of myogenesis in skeletal muscle has been described as being 'all-or-none' in nature, 
meaning that cells integrate mUltiple signals to detennine whether to continue to proliferate, 
or switch to a terminally differentiated state, but there are no characterized 'transitional' cell 
states. MyoD, and the highly related factor Myf5, seem to serve as nodal points in the 
process, integrating multiple signals to make decisions about the mutually exclusive 
processes of growth and differentiation (Weintraub et aI., 1991). Given the failure of RMS to 
differentiate while expressing MyoD, this suggests one or more mechanisms are operational 
in RMS that interfere with MyoD activity and function, trapping the tumor cells in a 
proliferative state. 
Initial work from our lab demonstrated that MyoD target activation was compromised 
in RMS, while MyoD itself exhibited no defects. Specifically, MyoD showed low activity in 
measures of transcriptional activity on myogenic reporters in RMS cell culture systems, but 
chimeric proteins made up of the DNA binding region of a Gal protein and MyoD activated 
targets many times more strongly. Further, fonnation ofheterokaryons between RMS cell 
lines and nonnal fibroblasts, but not between RMS cell lines themselves, led to a rescue of 
MyoD activity and a restoration of the ability of RMS to differentiate into skeletal muscle 
(Tapscott et aI., 1993). Taken as a whole, this work suggests two, non-exclusive 
possibilities: that RMS 1) lack a necessary activating factor that is not skeletal muscle or 
myoblast specific and is provided by the fibroblasts, and/or 2) lack one or more inhibitory 
factors that act to downregulate other inhibitors and thus contribute to activation. 
We have recently expanded the initial work on compromised MyoD activity in RMS 
and identified mUltiple other bHLH myogenic inhibitors as being present in RD cells, a cell 
culture model of the embryonal subtype (McAllister et aI., 1969), and contributing to the 
block in MyoD-mediated differentiation. We identified both MSC (musculin, aka MyoR), a 
transcription factor initially described as inhibiting myogenesis (Lu et aI., 1999), as well as a 
previously uncharacterized splice fonn ofE2A, one of the E-proteins, that we termed E2A-
2/5. Both factors act in a repressive manner on MyoD activity in RD cells and, in the case of 
MSC, compete with MyoD for a limiting quantity ofE-proteins to serve as a 
heterodimerization partner (Yang et al., 2009). 
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Remarkably, even given multiple bHLH inhibitors of my ogene sis present in RMS 
cells, we have found that introduction of a forced protein heterodimer of MyoD and a full-
length E2A (termed MyoD~E) leads to differentiation of the RD cells in whioh it is 
expressed. Notably, the activity of the forced dimer led to the downregulation of numerous 
myogenic inhibitors at tho RNA and protein level. Our findings have led us to propose a 
model in which ILMS are trapped in a proliferative state due to a 'balancing act' between the 
competing actions of a variety of inhibitory factors and the activating ability of MyoD and a 
full-length E-protein. When the balance is shifted in the direction of activation, through 
either a suffieient level of interference with the inhibitory factors or a enhancement 
to the activating potential of MyoD, a negative feedback loop mediated by MyoD is 
established, tips the balance, and locks in differentiation. 
If RcMS are poised in a balanced state between the activity of inhibitory and activating 
factors, other manipulations of factors that affect the balance should also result in 
differentiation. Indeed, in agreement with this model, recent publications have demonstrated 
that downregulation of a histone methyltransferase associated with inhibition (Lee et al., 
2011), interference with a transcription factor that inhibits myogenesis (Sang et al., 2008), 
and introduction of a pro-myogenic microRNA (Taulli et al., 2009) are all capable of pushing 
differentiation in rhabdomyosarcomas. Taken together, it suggests not only that RMS are 
representative of a point in normal myogenic differentiation, but that examination of other 
factors involved in normal differentiation should serve as a means to identifY additional 
differentiating agents for RcMS and expand the possibilities for therapeutic targets. 
To search for additional factors of importance in the proliferation-differentiation 
balance, we sought to determine 1) if potential myogenic co-factors that have recently come 
to our attention due to our determination of the genome-wide occupancy of MyoD in 
myogenic cells (Cao et al., 2010) can affect this balance, and 2) what factor(s) induced by the 
forced MyoD~E dimer could establish a negative feedback loop and lock in the 
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differentiation process. We report here that the MyoD-targeted transcription factors RUNXI 
and RP58 are both individually sufficient to drive myogenic differentiation in ReVIS culture 
models, and seem to support the process of myogenesis in distinct, as well as overlapping, 
fashions. Further, we report that both they, as well as the forced MyoD dimer, upregulate the 
pro-myogenic microRNA miR-206 when expressed in RMS, suggesting a common 
integration point for myogenesis. Finally, we offer evidence that the inhibitory bHLH 
protein MSC, an indirect miR-206 target, interferes with miR-206 expression by occluding 
an E-box that MyoD needs to occupy to drive high levels of miR-206 expression. Taken as a 
whole, our data suggests the existence of a multi-factorial epistatic relationship between 
MyoD, RUNXI and RP58 that serves to regulate the expression of a microRNA key to 
making the decision of myogenic and rhabdomyosarcoma cells to switch to a state of 
terminal differentiation. 
Results 
RUNXI and RP 58, cooperative transcription factors for myogenesis, are sufficient to 
differentiate rhabdomyosarcoma cells 
Our recent analysis of MyoD chromatin immunoprecipitation coupled to high-
throughput sequencing (ChIP-Seq) has identified potential transcription factor binding sites 
for factors that could affect myogenesis, including both those with well-known (eg. Meis) 
and less-known (eg. Runx1, RP58) roles in myogenic cells (Cao et al., 2010). We 
hypothesized that one or more of these factors might be aberrantly regulated or otherwise 
lacking in RMS, and focused on factors with less- or unknown roles in myogenesis. 
RUNXI is a runt-related transcription factor best known for its role in hematopoiesis 
and acute myeloid leukemia (AML) (Cohen, 2009), and while it is expressed in developing 
skeletal muscle cel1s (Zhu ct al., 1994) and plays a role in denervated muscle (Wang et al., 
2005), its role in developing muscle is uncharacterized. The RUNX1 binding motif is 
associated with MyoD-bound sites in differentiated myotubes and we have previously shown 
that RUNXI expression is induced both by the myogenic feed-forward network (Penn et al., 
2004), and the action of the forced MyoD~E dimer in RMS (Yang et al., 2009). qPCR 
confirmed that RUNXllevels increased with the forced dimer, and that it is expressed at 
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higher levels in both normal fibroblasts and myotubes created by MyoD action in fibroblasts 
(Fig 2.IA). 
The binding motiffor RP58, also known as ZNF238, is associated with MyoD bound 
sites that decrease in occupancy during differentiation, and, like RUNXl, increases in level 
with the action of the MyoD~E dimer and is expressed in myotubes (Fig 2.IB). Recent work 
has identified RP58 as being a crucial factor in myogenesis that directly downregulates the 
inhibitory ld factors (Yokoyama et aL, 2009), factors that can interferc with the formation of 
functional MyoD-containing heterodimers. 
Lentiviral expression vectors for each factor were cloned and transduced into RD 
cells. Myotubes that stained strongly for myosin heavy chain (MHC) cxpression, a marker of 
myogenesis, were observed to form specifically in the RUNXI and RP58 infected conditions 
as compared to either non-infected cells or cells infected with a titer-matched GFP virus (Fig 
2.IC). Muscle-specific creatine kinase (CKA1), a myogenic marker, increased in both cases 
(Fig 2.ID), and EdU labeling over a 24-hour period showed a significant decrease in the 
number of labeled RD cells when expressing either factor, though effect was more 
dramatic with those infected with RIT\IXI (Fig 2.1E). This differentiation does not appear to 
be cell-type specific, as RhJT cells, an alveolar subtype cell culture model, expressing 
RUNXI show an increase ofMHC at the protein level and CKM at the RNA level (data not 
shown). As in normal myogenesis, expression of RP58 causes both ID2 and ID3 to decrease 
(Fig 2.IF). As a further control, increased expression ofRP58 and RUNXI in response to 
introduction of the virus was confirmed (Fig 2.2). 
A/orced MyoD~Eprotein dimer, RUNXl, and RP58 all increase the pro-myogenic 
microRNA miR-206 when expressed in RMS cells 
Since the forced MyoD~E dimer induces both RUNXI and RP58, and both factors are 
sufficient to differentiate RMS cells, we sought to determine if all the factors act through a 
common mechanism. Given that we have previously identified the downregulation of 
multiple myogenic inhihitors in response to expression of the MyoD~E dimer, we 
hypothesized that a microRNA would be the most parsimonious mechanism by which it 
could act. We performed microRNA microarrays with RNA from RD cells infected with 
either MyoD~E or control retrovirus to determine what microRL"JAs were altered by 
MyoD~E expression. 
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A relatively small number of microRNAs changed expression, but miR-206, a 
microRNA that has been shown to induee myogenic differentiation (Kim et aI., 2006; Taulli 
et aI., 2009), was the most eonsistently increased (Table 2.1). Increase of mature miR-206 in 
response to MyoD~E was confirmed by miRNA Northern blotting (Fig 2.3A, upper panel), 
as was miR-133b, a miRNA from the same primary transcript and another positive hit on the 
array (Fig 2.3A, second panel). Other microRL"JAs are maintained either at a constant level 
(Fig 2.3A, middle panels), or are decreased (Fig 2.3A, bottom panel) in response to the 
forced dimeI'. The constant level ofmiR-29b in response to the forced dimer is particularly 
notable, since miR-29b has previously been described as participating in a NFKB-mediated 
transcriptional program in RMS and driving differentiation (Wang et a1., 2008). RT-PCR 
using primers in the presumptive human primary transcript containing miR-206 showed a 
substantial increase, further suggesting the increase is at the level of transcription (Fig 2.3B). 
microRL"JA Northern blots of RD cells differentiated through RUNXI and RP58 expression 
found that, as with the forced dimer, miR-206 levels were increased in both cases (Fig 2.3C), 
with an increase in primary transcript (data not shown). miR-206 levels in C2C12 cells, a 
myogenic cell culture model, showed that miR-206 expression changes in proliferative 
versus differentiated RMS resembled the changes as C2C12 cells shift from beginning 
myogenesis (90% confluency) to myotubes (DM) (Fig 2.3D). 
While miR-206 is known to be directly regulated by MyoD binding (Rosenberg et aI., 
2006), its relationship to RUNXI and RP58 is unknown. To test the hypothesis that RUNXI 
directly cooperated with MyoD in its regulation, the response of a miR-206 promoter 
luciferase reporter to RUNXI was examined (Fig 2.3E, black bars). RUNXI alone leads to 
a minor activation of the reporter, while RUNXI combined with MyoD leads to a synergistic 
activation of the rcporter compared to either individual transcription factor. Experiments 
using a reporter in which a putative RUNXI binding site has been mutated demonstrates not 
only that RUNXI fails to activate the reporter, either alone or when combined with MyoD, 
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but that the ability of MyoD, either by itself or when combined with E12, to activate that 
reporter is reduced (Fig 2.3E, grey bars). ChIP experiments also identified RUNX1 as 
binding in the miR-206 promoter (Fig 2.3F). Taken together, this suggests that RUNXI 
binding at the miR-206 promoter not only enhances the expression of miR-206, but is 
necessary for a fully competent activation by MyoD. RP58 did not lead to activation of the 
reporter (data not shown), suggesting that RP58 could be acting on miR-206 indirectly, 
possibly through its effect on the 1D proteins and MyoD dimerization. 
In agreement with previous reports demonstrating that miR-206 alone is sufficient to 
differentiate RMS cells, transfection of pre-miR-206 constructs into RD cells resulted in 
dramatic myotube formation (Fig 2.4A), an increase at the RNA level of the myogenic 
marker CKM (Fig 2.4B), and a withdrawal of such cells from the cell cycle (Fig 2.4C), with 
similar results in alveolar RMS model, RhJT cells (Fig 2.4D and data not shown). As 
would be expected from prior reports of its efrect on myogenic cells (Chen et aI., 2006), 
introduction ofmiR-133b did not lcad to RMS differentiation as judged by either 
morphology or gene expression (Fig 2.4E, F). 
MyoD activity positively regulates RUNXI and RP58 and RUNXI positively regulates RP58 
To further understand the relationship between MyoD, RUNXI, RP58, and miR-206, 
we sought to identify controlling factors of RUNXI and RP 58 expression. Previously, it has 
been shown that MyoD activates reporters driven by the RP58 promoter (Yokoyama et aI., 
2009). In agreement with this, induction with beta-estradiol ofMyoD activity in human 
fibroblasts stably expressing an estradiol-inducible MyoD demonstrated an increase in RP58 
expression at 6 and hours post-induction (Fig 2.5A). Interestingly, RP58 expression also 
increased in response to expression of RUN Xl in RD cells, but the converse was not true; 
RP58 did not upregulate RUNXI expression and actually led to a slight decrease (Fig 2.5B). 
ChIP data also identifies RUNXI as bound at the first intron of RP58, suggesting it functions 
directly to activate RP58 (Fig 2.5e). 
Bisulfite sequencing reveals no evidence for methylation of a RUNXI promoter (Fig 
2.6), so the possibility that the specific E-protein that serves as the MyoD dimer partner 
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controls RUNXl expression was tested. RD cells transduced with the MyoD~E dimer were 
compared directly to those transduced with a dimer comprised of MyoD and the E2/5 splice 
form of the E protein. 
An obvious morphological difference is apparent between MD~E and MD~E2/5 
expressing RD cells. Those expressing the forced dimer that included the full-length El2 
protein exhibit formation ofmyotubes in the great majority of cells on the plate, while those 
expressing the splice fonn of the dimer formed myotubes at a substantially reduced level (Fig 
2.7A). Western blots were used to confirm relatively equivalent expression of the forced 
dimers in infected cells (Fig 2.7B). MD~E expressing cells were found to express 
substantially more CKMrelative to MD~E2/5 expressing cells (Fig 2.7C), and higher 
RUNXI levels (Fig 2.7D), demonstrating that the specific bHLH protein partnered with 
MyoD is critical for competent expression of its downstream targets. Taken as a whole, the 
data suggests a unidirectional relationship proceeding from MyaD to RUNXl to RP58 and 
then miR-206, with RUNXI cooperating with MyoD atRP58 and miR-206, and RP58 
functioning indirectly at miR-206. 
miR-206 target genes are a subset a/the genes affected by RUNX1 and RP58 
To determine the genes regulated by RUNXI, RP58, and miR-206 in the context of 
the RMS differentiation, and further test our model that they are in an epistatic relationship, 
gene expression arrays were performed on RNA from RD cells differentiated by each one of 
the aforementioned factors and compared to RD cells infected with a GFP-expressing virus. 
GO analysis of the effects of each individual factor ranked by most significant p-values 
identified multiple muscle related categories for upregulated genes, with 5 of the 10 most 
significant categories shared between all factors (Table 2.2). In agreement with our 
hypothesis of an epistatic relationship, the number of genes that were identified as being 
significantly regulated (fold change> 2, FDR <0.05) by each factor became sequentially 
reduced from RlJNXl (735) to RP58 (617) to miR-206 (355). Also as predicted, the target 
overlap between individual factors was substantial, as was the overlap between all three (Fig 
2.8A), and there was substantial correlation between target genes (Fig 2.8B). As would be 
expected if the effects of RUNXI and RP58 on RMS are mediated through miR-206, gene 
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targets identified as being 'unique' to the miR-206 condition were also found in the RUNX1 
and RP58 arrays, but at lower fold-changes (Fig 2.8C, top). A similar, though weaker, effect 
was seen with the RP58 'unique' targets appearing in the RUNX1 array at lower fold-
changes (Fig 2.8C, bottom). 
RUNX1, RP58 and miR-206 were notable for having significant effects on a few key 
transcription factors and cellular signaling cascades involved in myogenesis (Table 2.3), as 
confirmed by RT-PCR (Figure 2.8D). All three led to a significant upregulation of the MRF, 
MYOG, a target ofMyoD (Cao et al., 2006). RUNX1 upregulated MEF2C and MEF2D, 
additional cooperative factors for MyoD activity (Penn et al., 2004). RP58 downregulated 
transcription factors of two groups of interest: 1) positive regulators of cell cycle (MYCN, 
RCOR2, E2F2) and 2) members of the HES/HEY family (HEY1, HES6, HEYL, HESJ). It has 
previously been demonstrated that interference with HES 1 contributes to RMS proliferation 
(Sang et al., 2008), and the HES/HEY family is known to be Notch responsive (Fischer and 
Gessler, 2007), a signaling pathway with myogenic inhibitory effects (Buas et al., 2009; 
Kopan et al., 1994; Lindsell et al., 1995). Among miR-206's most strongly downregulated 
targets were two members of the Notch signaling pathway, DLL3 and NOTCH3. 
The bHLH protein MSC occupies an E-box in the miR-206 promoter that MyoD requires for 
strong activation ofmiR-206 expression 
The above data suggests that miR-206 expression is a crucial decision point for 
myogenic differentiation, with sufficient expression capable of forcing differentiation. We 
have previously identified murine miR-206 as being regulated by MyoD binding (Rosenberg 
et al., 2006), but it was unclear whether MyoD itself is misregulated at miR-206 in RMS, or 
if another factor is responsible for the insufficient expression. We have previously shown 
that MyoD can bind targets in RMS (Tapscott et al., 1993), but that the bHLH protein MSC 
interferes with MyoD activity (Yang et al., 2009). Since MSC has been shown to be 
downregulated by miR-206 activity (Kim et al., 2006), we hypothesized MyoD and MSC 
might operate in opposing fashion at the level ofmiR-206 regulation. The miR-206 
luciferase reporter was tested with MSC, and co-transfection ofMSC along with MyoD and 
E12 almost completely ablated the ability of MyoD and E12 to activate the reporter (Fig 2.9, 
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black bars). This repression was also found when MSC was co-transfected with the forced 
MyoD~E12 dimer, suggesting the effect of MSC is due to binding on the DNA, not 
interference with the formation of MyoD:E dimers (Fig 2.10). 
MyoD was found by chromatin immunoprecipitation (ChIP) in the promoter region of 
the primary transcript for miR-206, in agreement with our previous findings in murine cells 
(Fig 2.l1A), and ChIP for acetylated H4 histones suggested the locus was open (Fig 2.l1B). 
In agreement with the ability of MSC to suppress the miR-206 reporter, ChIP demonstrated 
MSC also bound at the miR-206 promoter (Fig 2.11C), and at a comparable enrichment to 
that ofMyoD. 
Sequence analysis of the area assessed by ChIP located three potential MyoD- and/or 
MSC-binding E-boxes. We have recently performed ChIP-Seq using MyoD and MSC in RD 
cells, as well as MyoD in human fibroblasts differentiated to myotubes through the action of 
MyoD (see Chapter 3). The promoter region ofmiR-206 was examined and a strong MyoD 
peak observed at the same location interrogated by site-specific ChIP (Fig 2.12, top panel). 
MSC was also found in that area, though its peak of occupancy was at a different E-box 
compared to MyoD (Fig 2.12, middle panel). Electrophoretic mobility shift assays 
demonstrate that both types ofheterodimers can bind both of the E-boxes. Competition 
assays demonstrate that both heterodimers prefer the E-box at which MyoD binds, but that 
the relative level of that preference is greater for MyoD than MSC (Fig 2.13). 
To test the hypothesis that the MSC binding was interfering with MyoD activation of 
miR-206, the miR-206 reporter was mutated to scramble the MSC occupied E-box. Rather 
than becoming insensitive to MSC-mediated repression, the reporter instead became 
insensitive to activation by MyoD and E12 (Fig 2.9, grey bars). Taken together with the 
ChIP-Seq data identifying distinct sites of occupancy, this suggests that MSC is repressing 
the reporter by physically occluding an E-box that MyoD needs to occupy to fully activate 
miR-206. The ChIP-Seq data on MyoD in the human myotubes offers further support for 
this model. Compared to the MyoD peak in RD cells, there is a broadening of the MyoD 
peak in myotubes that appears to widen to include E-boxes located more proximally to the 
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start of the miR-206 transcript (Fig 2.12, bottom panel, arrow), suggesting that in 
myotubes, MyoD occupies additional positions. In addition, site-specific ChIPs identify a 
reduced level ofMSC occupancy at the miR-206 promoter in RD cells that undergo RUNX1-
mediated differentiation (Fig 2.14A), and MD~E differentiation (Fig 2.14B). 
Discussion 
We have previously proposed a model of RMS as being a balancing act between the 
activities of repressive and activating bHLH protein dimers, a balance that, when tipped by 
the MyoD~E dimer in the direction of activation, induces one or more factors 'X' to 
downregulate the myogenic repressors (Yang et al., 2009). Our present data offers further 
support for this model, demonstrating that the transcription factors RUNXI and RP58 can 
also drive RMS differentiation, and that miR-206 can function as 'X'. RUNXl enhances 
MyoD activity, at a minimum at miR-206, and judging from the expression array data, 
possibly at some of the key MyoD downstream targets (eg. MYOG, MEF genes). In contrast, 
RP58 activity downregulates not only multiple members ofthe inhibitory HES and HEY 
protein family, but multiple factors that drive cellular proliferation as well. But despite 
appearing to act directly at different targets, RUNXl and RP58 both ultimately serve to 
increase miR-206 transcription and lead to a terminally differentiated state, supporting our 
hypothesis that, regardless of the precise mechanism used to tip the balance in myogenic 
cells to favor differentiation, the end result is the same. 
MyoD acts in a complex feed-forward network to regulate its target genes, requiring 
some of its direct target genes to cooperate with it at later targets, allowing for fine temporal 
control. The data on RUNXl activity suggests that it fits into this network as a cooperating 
factor for MyoD to assist in regulating a subset of targets, such as RP58 and miR-206. While 
the regulation of RUNXI in myogenic cells will need further exploration, our data 
demonstrate that the E-protein partner of MyoD is an important factor in its regulation. 
RP58, on the other hand, does not appear to cooperate directly with MyoD at targets. Our 
data on RP58 regulation, motif analysis, and gene targets in this and previous work (Cao et 
al., 2010) suggests that the induction ofthis inhibitory factor serves two purposes: 1) to 
downregulate genes that inhibit myogenesis and promote proliferation, and 2) to interfere 
with MyoD binding itself, possibly assisting to shift the genes regulated by MyoD during 
development through that mechanism. Genome-wide exploration of the direct targets of 
RUNX1 and RP58 will be of great interest to further delineate their respective roles in 
myogenesis. 
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Musculin was originally identified as a bHLH protein that inhibits the process of 
myogenesis (Lu et a1., 1999), and our data suggest that, at least at miR-206, it functions by 
physically occluding an E-box that MyoD needs to occupy for full activation. A requirement 
for multiple MyoD-bound E-boxes to drive full target activation has been described before 
(Gilmour et a1., 1991; Lassar et a1., 1989; Piette et al., 1990; Weintraub et a1., 1990; 
Wentworth et al., 1991), but this is the first evidence that MSC can operate in this fashion 
and the first evidence for this sort of relationship in miR-206 regulation. Future work will be 
necessary to determine if this is a widespread mechanism at other myogenic targets, and if 
the close, but distinct pattern of MyoD and MSC binding is a common OCCUlTence. Given the 
fact that previous work has identified MSC as being dowmegulated by miR-206 activity 
(Kim et al., 2006), and MSC occupancy of the miR-206 promoter decreases after R.iV1S 
differentiate, this suggests MSC and miR-206 act in a classic negative regulatory loop, 
though possibly in an indirect fashion. 
Our work in rhabdomyosarcomas has demonstrated striking levels of similarity 
between the tumors and the biology in normal myogenic cells. This suggests, therefore, that 
mechanisms of differentiation utilized in nOlmal cells and model systems might be 
translatable to approaches to differentiate RMS. Certainly, the fmding that multiple factors 
capable of differentiating RMS all share regulation of miR-206 as a common point suggests 
that screens to identify drug gable targets that affect miR-206 regulation could negate the 
need for attempts at differentiation therapy to optimize micro RNA mimetics or delivery 
systems. 
Hematological malignancies have long been categorized and described on the basis of 
cell differentiation state. Our work suggests that the same may be possible for solid tumors, 
with rhabdomyosarcomas appearing as an arrested point of the myoblast to myotube 
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transition, trapped on the brink of the decision point to differentiate. While myogenic cells 
have been notable for more than two decades for the sharp demarcation between the 
processes of proliferation and differentiation, it is possible that this is a lesson more broadly 
applicable to other cell and tumor types. bHLH factors control cell fate and differentiation in 
multiple cell types, and experiments in tumors from such systems may identify not only the 
existence of other 'tipping points', but a more widespread utility to manipulating the 
controlling factors in such systems to stop the growth of tumor cells. 
Materials and Methods 
Trizol- Acid Phenol RNA Isolation 
Cells from one 10 cm plate for each biological condition were rinsed once with PBS, 
then scraped up into 1 mL of Trizol (Invitrogen). After vortexing to the point of no visible 
clumps, tubes were incubated at room temperature for five minutes. If necessary, Trizol 
solutions were frozen at -80° C before further processing. To continue RJ'JA isolation, 200 ul 
of chloroform were added to each tube. After 15 seconds ofvortexing, tubes were incubated 
at room temperature for 2 minutes, then spun at 10,600 RPM for 15 minutes at 4° C in a 
tabletop microcentrifuge. The aqueous layer (approximately 600 ul) was removed to a new 
tube, then an equal volume of isopropanol was added, mixed, and then incubated at -20° C 
for 30 minutes. After incubation, tubes were spun at 4° for 20 minutes at 14,000 RPM in a 
tabletop centrifuge. After visualization to ensure a visible RNA pellet had been precipitated, 
the solution was removed. One mL of75% ethanol was added to the tube, vortexed and then 
spun at 9500 RPM at 4° C for 5 minutes in a tabletop centrifuge. The RNA was then 
resuspended gently, with pipetting, in 400 uL of DEPC-treated water at room temperature. 
An equal volume of acid phenol (Ambion, pH 4.5) was then added to the resuspended RNA, 
vortexed for 3-5 seconds to mix thoroughly, and the tube then spun at 12000 RPM at 4° C for 
15 minutes. An aqueous layer of approximately 380 uL was recovered and an equal volume 
of chloroform added. Vortexing and spinning was repeated exactly as in the acid-phenol 
addition step, and an aqueous layer of approximately 360 uL recovered. 3 M sodium acetate 
solution was then added to reach a final concentration of 0.3 M (40 uL to 360 uL recovered 
RNA solution), and, after mixing, 1 mL of 100% cold ethanol added. After thorough mixing 
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by inversion, the tubes were then placed in a cold bath made of dry ice and 95% ethanol for 5 
minutes. Tubes were then spun at 14,000 RPM for 20 minutes at 4° C in a tabletop 
centrifuge. The precipitated pellet was visualized, the supe111atant removed and the pellet 
washed in 1 mL of75% cold ethanol with briefvortexing. The tube was spun for 5 minutes 
at 4° at 9500 RPM and all the ethanol carefully removed from the pellet. After air drying for 
approximately 10 minutes, to a point where there was no visible moisture, but before the 
center portion of the pellet tu111ed transparent, the pellet was resuspended in 50-75 uL of 
nuclease-free water. RNA concentration was checked by UV spectroscopy or Nanodrop 
(Thermo Scientific) and stored at -80° C. 
microRNA Northern Blots 
Northern blot ladder preparation: Radioactively labeled ladders were prepared fresh for each 
experiment. 100 ng of 10 bp DNA ladder (Ambion) was combined with I uL of lOx PNK 
Buffer (NEB), 6 uL of water, 1 uL ofT4 PNK enzyme (NEB) and 1 uL of a 1:500 dilution of 
yp32 -ATP (PerkinElmer). The mixture was incubated at 37° C for 30 minutes, and then 
incubated on a heat block at approximately 95° C for 5 minutes to denature the enzyme. 
Aerylamide gel preparation: A 15% polyacrylamide gel was prepared fresh for each 
experiment the same day. A small (15 mL) Erlenmeyer flask was used to combine 5.5 mL of 
40% 1: 19 acrylamide, 1.1 mL of lOx TBE (Tris-Borate EDTA solution), 330 uL of DEPC-
treated water, and 5.28 g of urea. To make a homogenous solution, the flask was 
microwaved at 100% power in a standard microwave for 5 second intervals three times, with 
5 - 10 seconds of swirling of the flask after each interval. After the solution was completely 
homogenous, it was allowed to cool for approximately 5 minutes at room temperature and 
then filtered through a 0.45 U1n syringe filter into a 15 mL conical tube with a screw cap 
(Falcon). To that filtered solution, 66 uL of 10% APS (ammonium persulfate) was added 
first, and then 6.6 uL ofTEMED. After inversion of the tube to mix, the solution was then 
poured into a gel casting apparatus that had been set up using 0.75 mm combs and spacers, 
and a comb with 10 wells. After allowing the gel to set for approximately 30 minutes, the 
comb was carefully removed and wells cleaned out with a small piece of filter paper and 
gentle pipetting of the running buffer (see below). 
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Running the samples: 25 ug of RNA, prepared using the Trizol-acid phenol approach, was 
used for each lane. Samples were concentrated in a speed vacuum as necessary to reach a 
volume of5 - 8 uL. To each sample, an equal volume of2x loading dye (Ambion Gel 
Loading Buffer II) was added. Dye was also added as with the RNA samples to the ladder 
prepared above. All samples and the ladder were then incubated in a 65° C water bath for 15 
minutes, and then moved immediately to ice for 10 minutes. During this time, the solidified 
gel prepared above was placed in a gel-running apparatus, as used standardly for Western 
blots, in IX TBE buffer and pre-run at 100 V for at least 10 minutes. After samples and 
ladder were on ice for 10 minutes, they were immediately loaded (the entirety of their 
volume) onto the gel, taking care to not load anything in the two wells on either edge. The 
gel was run first at 100 V for 1. 5 hours then, after the lower dye front had reached 
approximately halfway the distance down the gel, run at 150 V for another 1.5 hours, until 
the lower dye front just reached the bottom. 
Transferring and hybridizing the samples: The samples were transferred to a nytran SPC 
membrane in IX TBE buffer at 250 rnA for 45 minutes in standard Biorad wet transfer 
apparatus. The transfer components were assembled in the IX TBE buffer in the following 
order, listed in the order from closest to the clear side of the transfer cassette to closest to the 
black side of the cassette: sponge, 2 Whatman papers, membrane (presoaked in water before 
being placed into the TBE), gel, 2 Whatman papers, sponge. The assembled components 
were gently pressured in a rolling fashion with a pipette tip to make sure no bubbles were 
present. The cassette was then latched closed, and placed into the electrical apparatus so that 
the clear side of the cassette faced the positive pole (the red side on Biorad transfer 
materials). After 45 minutes of transferring, the cassette was disassembled, and the 
membrane was UV -crosslinked for 2 minutes on an automatic setting (Stratagene UV 
Stratalinker 1800). The blot was washed 3 times with normal water and then placed into a 
hybridization tube. The blot was prehybridized for 2 hours at 35° C in a rotating 
hybridization oven with 12 mL ofUItra-hybe buffer (Ambion) that had been heated briefly to 
65° C to go into solution then cooled to room temperature before addition to the blot. During 
this prehybridization, the probe(s) was/were prepared. The following components were 
combined: 14 uL of water, 1 uL of 10 uM oligo, 2 ofT4 PNK enzyme, 2 uL of lOx PNK 
buffer, I uL of undiluted yp32_ATP and incubated for 30 minutes at 37° C. Probes were then 
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heated on the heating block for 5 minutes, as with ladder preparation. Each probe was then 
brought to a final volume of 50 uL with double distilled water, and run through a G-25 
column (GE Healthcare) as per manufacturer's directions to purify and the elution collected. 
After prehybridization was completed, purified probe was added to the blot and hybridized 
with rotation ovemight at 35° C. The next moming, the blot was washed twice in 2X 
SSC/0.5% SDS for 25 minutes each time at room temperature with rocking. Blots were 
removed from wash solution, allowed to drip dry, and then wrapped in plastic wrap before 
being taped in a film cassette, blue X-ray film added, and allowed to expose for varying 
lengths of time at -80° C. 
Stripping blots/or serial probing: To re-probe blots, they were first stripped for 2 hours at 
85° C in an excess of 1 % SDS with vigorous rocking. Blots were then rinsed once with 
normal water, and prehybridized as above before the addition of new, freshly prepared probe. 
Probe Sequences: microRNA probes consisted of the reverse complement of the sequence of 
mature microRNA of interest. Probe sequences were: miR-206: 
CCACACACTTCCTTACATTCCA; miR-133b: TAGCTGGTTGAAGGGGACCAAA; 
miR-29b: AACACTGATTTCAAATGGTGCTA; miR-16: 
CGCCAATATTTACGTGCTGCTA; miR-199a*: TAACCAATGTGCAGACTACTGT 
microRl~A Transient Transfections 
pre-microRNA constructs for miR-206, miR-1 and miR-133b were purchased from 
Ambion. Reverse transfections were done at final concentration of25 uM of the pre-miRNA 
using siPORT NeoFX (Ambion) as per manufacturer's directions. An appropriate volume of 
pre-miR was diluted into 100 uL ofOpti-mem media (Invitrogen) and then mixed with 5 uL 
ofsiPORT that had been diluted in the same manner. After a 10 minute incubation at room 
temperature, 1 x 105 RD cells were mixed in a 9: 1 ratio of cells to transfection material and 
placed at 37° C. After 72 hours of growth, cells were shifted to low-serum differentiation 
media for 24 hours before harvested or fixed for further analysis. 
Chromatin Immunoprecipitation 
All ChIPs were perfonned on RD cells transduced with Babe-based retroviruses. 
After 16 - 24 hours of infection in the presence of 8 ug/mL polybrene, and 24 hours of 
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recovery, cells were selected for 40 - 48 hours in 1.5 ug/mL puromycin to eliminate non-
infected cells. Cells were then washed repeatedly and shifted to low-serum differentiation 
media for 24 - 28 hours before harvesting. Cells were washed twice in PBS + 2% serum, and 
then fixed for 11 minutes at room temperature in a 1 % PBS formaldehyde solution (5 rru\1 
HEPES pH 8.0,10 mM NaCl, 0.1 mM EDTA, 0.05 mM EGTA). The fonnaldehyde was 
quenched with the addition of glycine to a final concentration of 0.25 M. After removal of 
the solution, cells were washed twice with ice-cold PBS, and scraped into PBS with the 
addition of PM SF and complete protease inhibitors (Roche). Cells were spun down at 1100 
RPM at 4° C, and then resuspended in 2 mL oflysis buffer (1 % SDS, 5 mM EDTA, 1 % 
Deoxycholate, 50 mM Tris pH 8.0) for lO minutes on ice. Sonication was performed using a 
probe sonicator (Fisher, Sonic Dismembrator Model 500) at 45% amplitude for 3 minutes 
total, with cycles of 30 seconds on and 59 seconds off. This results in chromatin sheared to 
sizes of roughly 150 600 bp long. Chromatin was then spun at 14000 RPM for 10 minutes 
at 4° C and 100 uL ofthe chromatin set aside at -20° to use as input. The remaining 
chromatin was diluted 1: 10 in dilution buffer (1% Triton X-lOO, 2 mM EDTA, 150 mM 
NaCI, 20 mM Tris pH 8.0) and preeleared for 2 hours rocking in the cold with 200 uL 
Protein A/G agarose beads (Upstate). Beads were spun down for 1 minute at 700g and the 
chromatin then divided to immunoprecipitate overnight at 4° with nutation with 20 uL of 
antibodies. For transcription factor ChIPs, 5 6 mLs of chromatin were used, and I mL was 
used for histone modification ChIPs. Control precipitations were performed using equal 
volumes of chromatin. The following day, 20 uL of Protein A/G beads were added, and the 
mixture rocked in the cold for an additional 2 hours. Beads were harvested by centrifugation, 
and then rocked sequentially in Paro Buffer 1 (0.1 % SDS, 1 % Triton X-I 00, 2mM EDTA, 20 
mM Tris pH 8.] 150 mM NaCl), 2 (0.] % SDS, 1 % Triton X-I 00, 2 mM EDT A, 20 mM Tr1s 
pH 8.1, 500111:\1 NaCI), and 3 (0.25 M LiCI, 1% NP-40, 1% Deoxycholate, 1 mM EDTA, 10 
mM Tris pH 8.1) before a final wash in TE (lO mM Tris pH 8.0, ImM EDTA). All washes 
were 10 minutes in length at room temperature, and the beads were harvested between each 
wash with centrifugation in a table-top centrifugc at 2500 RPM for I minute. After the TE 
wash, beads were resuspended in 150 uL elution buffer (1% SDS, 0.1 M NaHC03) and 
allowed to sit at room temperature for 15 - 20 minutes with occasional gentle tapping before 
being placed in a 65° water bath overnight. Inputs were also placed at 65° after having SDS 
and NaHC03 added to the same final concentration. The following day, the elutions were 
separated from the beads and purified using the PCR purification kit (Qiagen) according to 
manufacturer's directions. Elutions were done in 50 uL Buffer EB. 
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Antibodies used were as follows: Runxl (Abeam, ab23980), MyoD (Tapscott et aI., 1988), 
MSC (Santa Cruz, sc-9556X), Acetylated Histone H4 (Upstate 06-866). Primers used for 
site-specific amplification were: miR-206: CAACAAGCACCCAAAACAGA, 
TTCCACATTCACGCAGAGAG; HBB control locus: AACGGCAGACTTCTCCTCAGG, 
AGTCAGGGCAGAGCCATCTA; miR-20610cus for Runx binding: 
TGGCATATGTTTCCCCATTT, GTTGAGCCACTCAGGGTCTG; RP58: 
CCACAGTCAGCTGGATCAGA, GAGGGCAGCTCACAAGGT AG; RUNX control locus 
(MYH8 enhancer): TGTGGCTATCTCTGTGTGCAG, TTAGATTTTGGGGGATGGTG 
Expression microarrays 
RNA was isolated using the RNeasy mini kit (Qiagen) from RD cells infected with 
either RUNX1-, RP58-, miR-206- or GFP-expressing lentiviruses and allowed to 
differentiate for 72 hours. Each condition was performed with 3 independent biological 
replicates. RNA was hybridized to Illumina Human HT-12 v4 BeadChips. Analysis was 
performed in R/Bioconductor using the lumi and linuna packages with annotations found in 
the lumiHumanAll.db package. p-values were adjusted to account for multiple testing using 
Benjamini and Hochberg's method, and cut-offs for significant changes were a FDR <0.05 
and a fold-change >2. GO category enrichment tests were performed using the conditional 
algorithm of the GOstats package and a gene "universe" of any gene with a GO annotation 
that was called as "present" in at least one of the array datasets. 
EdU labeling, Western blots, and cell stains 
After 24 hours in low-serum differentiation media, cells were shifted to 
differentiation media supplemented with EdU at a final concentration of 50 uM (Invitrogen) 
and incubated for a further 24 hours. Cells were then fixed and stained according to the 
manufacturer's protocols using the Click-iT kit, and total nuclei and EdU positive nuclei 
counted by hand. 
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Western blots were performed on whole celllysates collected in Laemelli buffer 
containing 10% beta-mercaptoethanol. All blots were blocked in 3% milk (w/v) in 0.5% 
Tween-20-containing PBS before incubation with primary antibody (MHC: MF-20, MyoD: 
5.8A, Runx!: Abeam, ab23980), a HRP-conjugated secondary antibody, and 
chemiluminescent detection (Amersham). 
Cells were fixed with 2% paraformaldehyde for 6 minutes at room temperature before 
permeabilization with Triton X-IOO. Myosin heavy chain was detected with the MF-20 
antibody, and nuclei detected with DAPI. 
microRNA microarrays 
RNA was isolated using acid-phenol purification from RD cells transduced with 
either MD~E or empty vector retroviruses and differentiated for 24 hours after puromycin 
selection. miRNAs were labeled using Exiqon's miRCURY labeling kit, and then 
competitively hybridized to in-house spotted miRNA arrays (FHCRC core facility). Cut-offs 
for significant changes were a FDR <0.05 and a fold-change >2. 
qPCR and RT -PCR 
All qPCR was performed using SybrGreen from Bio-Rad on an Applied Biosystems 
7900HT. Relative expression levels were calculated cDNA dilution standard curves or 
delta-delta Ct calculations. All values are repOlied as the mean + SEM of at least 3 
independent biological experiments. Primers used for amplification were as follows: CKi\1: 
CCAAGTTCGAGGAGATCCTC, AGCTGCACCTGTTCTACTTCG; TIMMI7b: 
GGAGCCTTCACTATGGGTGT, CACAGCATTGGCACTACCTC; ID2: 
CCCAGAACAAGAAGGTGAGC, AT AGTGGGATGCGAGTCCAG; ID3: 
CTGGACGACATGAACCACTG,GTAGTCGATGACGCGCTGTA;MYOG: 
GGCCACAGATGCCACTACTT,GCTTTACCTCCCTGGAAAGG;MEF2D: 
CTCTTTGCCGTGACAACACC, CTCATGAACGGTCTGGGAAC; MYCN: 
CACAAGGCCCTCAGTACCTC, CACAGTGACCACGTCGATTT; E2F2: 
CTACACACCGCTGTACCCG,CCAGATCCAGCTTCCTTTTG;RCOR2: 
TCAGCTCATCTCCCTCAAGC, T AGTGGATCAATACCGCCCT; HEYL: 
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ATCGACGTGGGCCAAGAG, ATCCCTCTGCGTTTCTTCCT; HEYl: 
TGGATCACCTGAAAA TGCTG, CGAAATCCCAAACTCCGAT A; pri-miR-206 (regular 
RT-PCR): GTTTCGGCAAGTGCCTCCT, CTCTTGCTTCCTTGGTGAGG; (qPCR): 
TGCTGTGAGTGAGGTTCAGG, 
CAGGGTTGTGGTGTGAAGTG; NOTCH: TGTGCAAATGGAGGTCGTT, 
CCTGAGTGACAGGGGTCCT; DLL3: CATCGAAACCTGGAGAGAGG, 
CCTGCGCGCTGAA TGTC. 
Plasmid construction 
The coding sequences of RUNXI and RP58 were cloned into 
pRRLSIN.cPPT.PGKlGFP.WPRE in the BamHIISalI sites. The miR-206lentivirus was 
purchased from Open Biosystems. Lentiviral supernatant was produced by the FHCRC core 
viral facility. MD~E2/5 was cloned into the pCLBabe backbone and packaged using BBS-
mediated calcium precipitation into Phoenix cells. For the miR-206 promoter luciferase 
reporter, a ~2.5 kb piece of DNA upstream of human miR-206 was amplified using the 
primers GAA TGCT AGCCTGTCCTTGATTTT ACCC and 
CAAT AGATCTTTGTGCAGCT ACAGTCTA and cloned into the NheI/BglII sites in pGL3 
basic. 
Cell culture, transient transfections and luciferase assays 
RD cells were maintained in DMEM with 10% bovine calf serum and 1 % Pen-Strep 
(Gibco). Low-serum differentiation media consisted of DMEM with 1 % horse serum, 1 % 
Pen-Strep and 10 ug/mL insulin and transfenin. Transient transfections for luciferase assays 
were performed using Superfect and a total of 3 ug of DNA a total of 1.5 ug of plasmids 
being tested for their effect on the reporter, 1 ug of luciferase reporter, and 0.5 ug of renilla 
internal control (renilla-CS2) (Qiagen). Luciferase assays used the Dual-Luciferase Assay 
kit (Promega) according to manufacturer's directions. All results were conected to co-
transfected Renilla-pCS2 and are reported as the mean ± SEM of at least 3 independent 
experiments, each experiment having 3 biological replicates of all conditions. 
Electrophoretic mobility shift assays 
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Electrophoretic mobility shift assays were performed as described previously (Davis 
et al., 1990). Briefly, proteins were translated in vitro using a rabbit reticulocyte lysate 
system (Promega) and synthesis of a single protein product of the correct size confirmed 
using parallel 35S-labeled translations. Equal volumes of translation product were used in 
each lane, and balanced with empty CS2 translated reactions or reticulocyte lysate alone. 
Mixtures were ineubated at 3 TC for 20 min in a DNA binding cocktail solution (either 20 
mM HEPES (pH 7.6), 3 mM MgCh, 1 mM DTT, 1 mM EDTA or 20 mM HEPES (pH 7.6), 
1.5 mM MgCb, ImM DTT, 1 mM EDTA, 50 mM KCI) before y_32p ATP-Iabeled 
oligonucleotide probes were added at room temperature for 15 min. Probe sequences were as 
follows (forward probes only listed): MSC-bound E-box: 
TGGA TGGGCAGCTGCTGCCCAT; MyoD-bound E-box: 
TGGCTCAACAGCTGCCAATGTC. Complexes were resolved on 6% polyacrylamide gels 
and exposed to radiographic film. 
Bisulfite conversion and sequencing 
Bisulfite reactions and sequencing were performed as has been described previously 
(Diede et aL, 2010). Primer sequences were: set 1: 
GGTAGGAGTTGTTTGTAGGGTTTTA, CCCACATCCCAAACTAAAAAAA; set 2: 
GGAGATTTGGAAAAAGAAAGTAGGT, AAAATCTTTCCTAACTAAAAAACTCTTC; 
set 3: GAGTTAAGTTTTAGGAATAGGGGTTT, CCCTCCCCCAAAACTAAAATACTA; 
set 4: GGTGTATGTAAGGTTGGGATTAATTT, 
CCACTTTCTAACTCTATCCCT AAAAAAA. 
Table 2.1 miRNA changes in response to MyoD~E12 expression in RD cells. 
Experiment 
Number 
Biological 
Replicate 
#1 
Biological 
Replicate 
#2 
Biological 
Replicate 
#3 
miRNA ID§ 
· hsa-miR-206, mmu-miR-206, rno-miR-206, dre-miR-206, 
gga-miR-206, mdo-miR-206, mne-miR-206, ppy-miR-206, 
xtr-miR-206 
hsa-miR-663 
I 
• mml-miR-133a, ppy-miR-133a 
I 
I hsa-miR-133a-133b 
· cel-miR-243 
hsa-miR-199a*, mmu-miR-199a*, bta-miR-199a*, dre-miR-
199*, a-miR-199*, xtr-miR-199a* 
hsa-miR-143 
hsa-miR-206, mmu-miR-206, rno-miR-206, dre-miR-206, 
gga-miR-206, mdo-miR-206, mne-miR-206, ppy-miR-206, 
i xtr-miR-206 
h 'R 125 'R 125 'R 125 b 'R 125 sa-ml - a, mmu-ml - a, rno-ml - a, ta-ml - a 
! hsa-miR-335, mmu-miR-335, rno-miR-335 
• mghv-miR-Ml-6 
I hsa-miR-196b, mmu-miR-196b, rno-miR-196b, mdo-miR-196b 
· ptc-miR4 78a-ptc-miR478b-ptc-miR4 78c 
dme-miR-6,dps-mir-6 
hsa-miR-199a*, mmu-miR-199a*, bta-miR-199a*, dre-miR-
• 199*, gga-miR-199*, xtr-miR-199a* 
hsa-miR-653 
hsa-miR-99b, mmu-miR-99b, rno-miR-99b 
ath-miR160a-, ath-miR160b-, ath-miR160c, gma-miR160, mtr-
miR160, osa-miR160a-, osa-miR160b-, osa-miR160c-, osa-
miR160d, ptc-miR160a-, ptc-miR160b-, ptc-miR160c-, ptc-
I miR160d, sbi-miR160d-, sbi-miR160a-, sbi-miR160c-, sbi-
• miR160b-, sbi-miR160e, zma-miR160a-, zma-miR160c-, zma-
i miR160d-, zma-miR160b-, zma-miR160e 
• cbr-miR-249 
osa-miR169f-, osa-miR169g, ptc-miR169r, sbi-miR169c-, sbi-
miR169d, zma-miR169f-, zma-miR169g-, zma-miR169h 
• hsa-miR-302a mmu-miR-302 
I ' 
osa-miR164c 
. 
- - - - - - - -
hsa mlR 206, mmu mlR 206, rno miR 206, dre mlR 206, 
I gga-miR-206, mdo-miR-206, mne-miR-206, ppy-miR-206, 
xtr-miR-206 
i 
I 
I 
I 
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Fe I (lOg2)* 
1.345; 
1.3225 
1.103 
1.015; 
] .0385; 
1.0005 
1.032; 
1.0155 
1.0215 
-1.015 
-1.025 
1.081 ; 
1.021 
-1004 
-1.021 
-1.025 
-1.0305 
-1.0325 
-1.0865 
1,106 
-l.11 
-1.1225; 
-1.137 
-1.182 
-1.2025 
-1.436 
1.3945 
! 
1,2045 
1.0395 
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Table 2 1 continued . , 
I hsa-miR-204, rnrnu-miR-204, rno-miR-204, dre-miR-204, fru- I 
miR-204, gga-miR-204-211, ggo-miR-204, mdo-miR-204, 
-1.0145 
mne-miR-204, ppa-miR-204, ppy-miR-204, ptr-miR-204, sla-
miR-204, ssc-miR-204, tni-miR-204a, xtr-miR-204 
i hsa-miR-548b 1.016 
• mmu-miR-684 -1.025 
I hsa-miR-376b -1.045 
rnrnu-miR-505 -1.0675 
hsa-miR-214, rnrnu-miR-214, rno-miR-214, age-miR-214, bta-
• miR-214, dre-miR-214, fru-miR-214, ggo-miR-214, mdo-miR-
-1.088; 
• 214, rnrnl-miR-214, rnne-miR-214, ppa-miR-214, ppy-miR-
-1.016 214, ptr-miR-214, sla-miR-214, ssc-miR-214, tni-miR-214, xtr-
miR-214 
ath-miR159a, gma-miR159, ptc-miR159a-, ptc-miR159b-, ptc-
-1.137 
miR159c 
I mmu-miR-467a -1.184 
• ce1-miR-84 -1.2475 
• hsa-miR-589 -1.258 
I dre-miR-27c, fru-miR-27c, tni-miR-27c 1.4145 
hsa-miR-549 -1.75 
Biological ath-miR394a-, ath-miR394b, osa-miR394, ptc-miR394a-, ptc-
Replicate miR394b, sbi-miR394a-, sbi-miR394b, zma-miR394a-, zma- 1.801 
#4 miR394b 
I aga-miR-9c, dme-miR-9c, d£s-miR-9c 1.252 
hsa-miR-206, mmu-miR-206, rno-miR-206, dre-miR-206, 1.247; gga-miR-206, mdo-miR-206, mne-miR-206, ppy-miR-206, 
I xtr-miR-206 1.2055 
r1cv-miR-rLl-11 1.14 
cel-miR-243 1.0905; 1.0415 
mmu-miR-679 1.0035 
dme-miR-9b, dps-miR-9b -1.0105 
I hsa-miR-20b, mmu-miR-20b, rno-miR-20b, gga-miR-20bxla-
miR-20, xtr-miR-20b i 
-1.119 
! hcmv-miR-US25-2-5p -1.1675 
i osa-miR441a-, osa-miR441b-, osa-miR441c -1.4745 
mmu-miR-291a-5p-291 b-5p, rno-miR-291-5p i -1.526 
§All miRNA names generated from the miRNA expression array are listed, regardless of 
whether the sequences are identical amongst species. 
* All changes are listed as the log2 value in order from most upregulated to most 
downregulated, within the restrictions ofFDR <0.05 and Ilog2 fold-change I > 1 for each 
independent biological replicate. If more than one change was identified for a single 
miR.1\,jA, they are listed individually. 
Bold miRNA names indicate those miRNAs found in more than one biological replicate. 
I 
I 
I 
I 
i 
I 
I 
I 
i 
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T bl 22 GO C t f ltd b RUNXl RP58 d oR 206 a e .. a egones 0 genes upregu a e V I , an mt -
GO 
Category Gene 
GO Terma P-valueb Sizec Countd 
RUNX1-
regulated 
genes 
Muscle filament sliding 1.49E-19 30 18 
Actin-mediated cell contraction 1.49E-19 30 18 
Actin filament-based movement 5.53E-18 40 19 
Structural constituent of muscle 1.93E-15 29 15 
Z disc 5.21E-14 33 15 
Heart process 5.77E-12 51 16 
Sarcomere 7.94E-12 32 13 
Muscle organ development 1.05E-09 175 I 
Blood circulation 1.33E-09 138 22 
• Actin cytoskeleton i 8.89E-09 168 I 23 
RP58-
regulated 
I genes 
Structural constituent of muscle 8.23E-ll 29 11 
Myofibril 9.40E-ll 84 17 
Muscle filament sliding 1.45E-10 30 11 
Actin-mediated cell contraction 1.45E-10 30 11 
Actin filament-based movement 4.84E-09 40 11 
Actin cytoskeleton 1.07E-08 223 24 
Muscle organ development 4.13E-08 175 20 
Myosin filament 8.04E-08 I 10 • 6 
Cell differentiation 9.43E-08 1241 64 
Developmental process I 1.22E-07 2251 97 
miR-206-
. regulated 
· genes 
Muscle filament sliding 1.06E-16 30 13 
Actin-mediated cell contraction 1.06E-16 30 13 
Actin filament-based movement 9.40E-15 40 13 
Sarcomere 2.17E-13 32 11 
Actin cytoskeleton 1.08E-12 223 22 I 
Muscle cell development 6.10E-12 63 l3 • 
• 
I Heart process 7.7SE-12 51 12 
Striated muscle cell 
differentiation 1.06E-10 78 13 
43 
Table 2.2, continued 
! Structural constituent of muscle 1.27E-IO 29 • 9 • 
Cardiac muscle contraction 2.27 E-l 0 20 . 8 
Bold categories indicate those that are common between RUNXl, RP58, and miR-206. 
aThe name of the indicated GO category 
bP-value associated with the GO category 
cThe total number of genes contained within the GO category 
dThe number of genes contained with the GO category found to be significantly 
regulated in the analysis. 
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Table 2.3. Select potential myogenic regulators affected by RUNXl, RP58, and miR-
206. 
-~ 
! 
I 
miR-2~ Gene RUNXIFC RP58FC 
Symbol (lOg2t (log2) FC (log2) i 
i Strong RUNXI regulation 
MYOG 2.01 I 1.28 1.17 
MEF2C 1.81 1.10 0.84 
lVIEF2D 1.50 0.37 i 0.69 
i Strong RP58 regulation 
MYCN -0.71 -3.34 -1.29 
RCOR2 -l.l1 -2.03 -0.86 
HEYL -0.69 -1.95 -0.24 
HES6 -0.23 -1.63 -0.39 
E2F2 -0.43 -1.67 -0.01 
HEY] 
I 
-0.53 -1.05 0.23 
I HES] * -1.09 -0.72 -0.41 
. Stronf( miR-206 ref(uiation 
i 
NO TCH3 -0.39 -1.5 -1.75 
DLL3 -2.07 -1.88 -1.93 
*Though it didn't reach the 2-fold change cut-off, HES] was included for its known role in 
RMS. 
aAll fold-changes are reported as the log2 value. 
Bold numbers indicate the fold-change in the analysis that originally identified the genes as 
being of potential interest. 
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Figure 2.1. Expression of RUNXI or RP58 leads to terminal differentiation of RMS 
cells. A) qPCR for RUNXI was performed in RD cells infected with a control virus, or the 
forced MyoD~E dimer (MyoD-E) as well as control (0 h) human fibroblasts and fibroblasts 
differentiated into myotubes (96 hr). B) RT-PCR for the two isoforms of RP58 in RD cells 
and fibroblasts as in lA. C) Myosin heavy chain (MHC) immunostains in RD cells either not 
infected, infected with a control GFP-expressing lentivirus (GFP control) or RUNX1 or 
RP58 expressing lentivirus. All cells were infected at equivalent MOls, and cells 
differentiated for 72 hours before staining. GFP was detected directly. D) qPCR for muscle-
specific creatine kinase (CKM) in RD cells infected with either RP58 or RUNX1 viruses. E) 
After 24 hours of differentiation, RD cells were pulsed for a further 24 hours with EdU-
containing differentiation media, before fixation and quantification of the percentage of EdU 
positive cells. D) qPCR for ID2 and ID3 in control and RP58 expressing RD cells. All 
qPCR data are normalized to TIMM17b expression, and the level in control cells is set to 1. 
All bar graphs represent the mean ± SEM of at least 3 independent experiments. *: p<0.05; 
**: p<0.01; ***: p<O.OOl; ****: p< lxlO-4 
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Figure 2.2. RD cells infected with RP58 and RUNXI viruses increase expression of the 
appropriate factor. A) RT-PCR for RP58 in RD cells infected with either a control virus or 
the RP58-containing virus. TIMM17b is used as a loading control. B) Western blot for 
RUNXI in control and RUNXI virus infected RD cells. The blot was then stripped and 
rcprobed for alpha-tubulin as a loading control. Bands were confirmed to be of the correct 
size. 
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Figure 2.3. MyoD-E, RUNXl, and RP58 increase miR-206. A) micro RNA Northern 
blots to detect the mature form of the indicated microRNAs in either control or MD~E 
expressing RD cells. B) RT-PCR using primers located the pre- and pri-miR-206 
sequence to detect the primary miR-206 transcript. TIMM17b is an internal control. C) 
microRNA Northerns as in 2A, in RD cells infected with either empty (control) retrovirus, or 
retrovirus expressing a transcription factor as indicated. D) micro~~A Northerns for the 
indicated miRNAs in C2C12 cells at various stages of differentiation ranging from 
undifferentiated myoblasts (50% GM), through beginning differentiation (90% GM) to 
myotubes (DM). E) Luciferase activity in RD cells using a miR-206 promoter driven 
reporter and transiently transfected factors as indicated. '206 Runx mutant' indicates that the 
repOlter has had a putative RUNXI binding site mutated to prevent RUNXI binding. 
Luciferase experiments were performed in triplicate, and are reported as the mean + SEM. 
F) RUNXI ChIP assays at the miR-206 promoter and a control locus before (eontrol) and 
after (RUNX 1) infection of the cells with empty or RUNX I-expressing retrovirus. PCRs 
were performed for the same number of cycles. The graph represents the mean ± SEM of2 
independent experiments. * : p<0.05 
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Figure 2.4. miR-206, but not miR-133b, differentiates RMS cells. A) Immunostains for 
MHC in RD cells transfected with either a pre-miR-206 RNA construct, or a negative control 
construct. Nuclei were stained with OAP!. B) qPCR for CKM in RD cells treated as in A. 
C) RD cells treated as in A were pulsed with BrdU for 24 hours and then stained and counted 
by hand to determine the extent of co-localization of MHC-expressing myotubes, and nuclei 
with BrdU. D) lmmunostains for MHC in RhJT cells that were treated as in A. E) qPCR for 
CKM in RD cells transfected with pre-miR -133 b or control. F) lmmunostains, as in part A, in 
RD cells transfected with either pre-miR-133b or contra\. All bar graphs are the mean ± SEM 
of at least 3 independent experiments, and qPCR results were normalized to TlMM17b. *. 
p<O.05; **: p<O.OI ; ***: p<O.OOl. 
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Figure 2.5. RUNXI and MyoD both positively regulate RP58 expression. A) lOTl/2 
fibroblast cells stably expressing an estradiol-inducible version of MyoD were induced to 
undergo myogenesis by addition of beta-estradiol to the culture medium. RNA was taken at 
the indicated timepoints and conditions, and qPCR performed to quantitate the relative levels 
of RP58 over time. B) qPCR for RUNXI and RP58 in RD cells transduced with virus 
expressing the converse factor. C) RUNXI ChIP assays at the intron of RP58 and a control 
locus before (control) and after (Runxl) infection of the cells with empty or RUNXl-
expressing retrovirus. PCRs were performed for the same number of cycles. The graph 
represents the mean ± SEM of 2 independent experiments. 
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Figure 2.6. RUNXI is not hypermethylated in RD cells. A) The upper panel indicates the 
location of primers designed to interrogate the methylation status of this RUNX l promoter 
region in a UCSC browser shot. Numbered panels below correspond to the numbered bands 
above. Darkened circles indicate a methylated CpG, while empty circles indicate an 
unrnethylated CpG. Each horizontal row indicates an individual sequenced clone. 
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Figure 2.7. A forced MyoD~E2/5 dimer does not fully activate myogenic targets. A) 
Light microscopy images of RD cells infected with either control virus or virus expressing 
either the MyoD~E or MyoD~E2/5 forced protein dimer and allowed to differentiate for 24 
hours. Arrows indicate representative cells that have appeared to form myotubes. B) 
Western blot for MyoD and alpha-tubulin, as a loading control, from cells treated as in 5A 
The size of the bands detected in MD~E and MD~E2/5 lanes correspond roughly to the 
calculated of the MyoD~E dimer. C) qPCR for CKMin RD cells treated as in 5A D) 
qPCR for RUNXl in RD. All qPCRs are represented as the mean ± SEM of at least 3 
independent experiments. *: p<O.05; **: p<O.Ol; ***: p<O.OOl. 
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Figure 2.8. RUNXl, RP58, and miR-206 function through common mechanisms. A) 3-
way Venn diagram representing the overlap between significantly regulated (fold-change >2, 
FDR <0.05) gene targets in RD cells differentiated either through RUNXl, RP58 , or miR-
206 expression relative to GFP-infected controls. B) Scatter plots showing pairwise 
comparisons of gene expression from the expression data used in SA. 'Cor' indicates the 
correlation for each comparison. C) Clustered bar graph demonstrating that the majority of 
genes listed as being 'uniquely' regulated by miR-206 in SA, are also regulated by RUNXI 
and/or RP58, but at lower levels of expression change. FDR was kept constant «0.05) in 
this analysis, and to be included as a 'shared' target, the change must occur in the same 
direction (either up- or down-regulated) in RUNXI and/or RP58 as in miR-206. D) RT-PCR 
for various gene targets from Table 2. TIMM17b serves as the internal control. 
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Figure 2.9. MSC represses MyoD activation of miR-206 and occupies an E-box MyoD 
requires. Luciferase assays in RD cells with constructs as indicated below the figure using 
either the miR-206 promoter luciferase repOlter (206) or one which the E-box that the peak 
ofMSC occupancy is located over has been mutated (206 Ebox mutant). 
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Figure 2.10. MSC inhibits the activation ofthe miR-206 reporter by the forced 
MyoD~E dimer. Luciferase assay using the miR-206 reporter with either MyoD and El2 
introduced individually or as the forced dimer, in the presence of two different amounts of 
co-introduced MSC. Ix indicates that the MSC transfected was equal to amount ofMyoD 
(or MyoD~E), and O.1x indicates that the MSC transfected was 1110th that amount. Values 
are represented as the mean ± SEM of 3 independent experiments. 
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Figure 2.11. Site specific ChIPs in RD cells. A) ChIP for MyoD in RD cells in 
differentiation media shows MyoD enrichment upstream ofmiR-206, but none at 
hemoglobin beta (control). B) Site-specific ChIPs in RD cells for acetylated histone H4, a 
marker of histone acetyltransferase activity and an open chromatin structure, at hemoglobin 
beta (control), miR-206, and the myogen in promoter (Myog). C) ChIP for MSC using the 
same primers as used for Part A. All ChIPs are represented as the mean + SEM of at least 3 
independent experiments. *: p<O.05; ** : p<O.Ol. 
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Figure 2.12. MyoD and MSC occupy distinct E-boxes in the miR-206 promoter. 
Screenshot from the human UCSC Genome Browser of the region that corresponds to the 
miR-206 promoter region. Mapped reads from ChIP-Seq for MyoD in RD and HFF cells are 
indicated, with the number on the left-hand y-axis indicating the number of reads mapped at 
the peak of occupancy. The location ofE-boxes are indicated at the bottom of the panel by 
the black rectangles. Vertical lines are drawn through the apparent highest points of 
occupancy for MyoD and MSC in RD cells. 
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Figure 2.13. In vitro assessment of MyoD and MSC binding in the miR-206 promoter. 
Electrophoretic mobility shift assays were performed using proteins as indicated and probes 
that represented the DNA sequence under either the E-box occupied most strongly by MyoD 
in RD cells (MyoD-bound E-box), or the E-box under the peak ofMSC occupancy (MSC-
bound E-box). Bound complexes were competed with cold competitor probes prepared at the 
indicated excess. 
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Fig 2.14. Differentiation of RD cells results in reduced MSC occupancy at the miR-206 
promoter. A) Site-specific MSC ChIP in RD cells infected either with an empty retrovirus 
(Control), or RD cells differentiated through the action of RUN Xl (Runxl). Values 
represent the mean + SEM from at least 3 independent replicates. B) ChIP for MSC at the 
miR-206 promoter in RD cells either treated with empty virus (control), or differentiated 
through the expression of the forced MyoD~E protein dimer (MD~E). Values are the 
average ± Std Dev of 2 independent experiments. Corrected relative enrichment equals 
relative enrichment at miR-206/relative enrichment at the control locus. *: p<O.05. 
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Chapter 3: Genome-wide binding of myogenic bHLH factors in human myogenic cells 
and rhabdomyosarcomas 
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Summary 
Rhabdomyosarcomas (RMS) are a pediatric tumor of skeletal muscle that express the 
myogenic bHLH protein MyoD but fail to undergo terminal differentiation. Previous 
experiments have determined that the DNA binding of MyoD in RMS occurs, but that there 
is a defect in its ability to activate myogenic targets. bHLH inhibitors of myogenesis have 
also been identified in RMS, but the relation of their binding to that ofMyoD is unknown. 
Here, we use chromatin immunoprecipitation coupled to high-throughput sequencing (ChIP-
Seq) to demonstrate that both MyoD and the bHLH inhibitor MSC bind widely throughout 
the genome of RMS cells, at both overlapping and unique sites, an effect driven partially by 
binding site sequence. Further, comparison of MyoD bound sites between RMS and normal 
human myotubes demonstrates differences in bound sites at a subset of locations with 
potential functional implications. One of these differences indicates that DNA binding of the 
transcription factor RUNXI associated with MyoD binding is underrepresented in RMS - a 
finding in agreement with our demonstration that expression of RUNXI differentiates RMS 
cells. 
Introduction 
High-throughput sequencing coupled to chromatin immunoprecipitation (ChIP-Seq) 
of transcription factors permits genome-wide assessment of DNA binding by the factors and 
the possibility to draw new conclusions about their functionality. While some factors have 
been found to bind in a restricted pattern that suggests a fairly direct correlation with gene 
activation, others have been found to bind in a surprisingly promiscuous fashion, exhibiting 
binding throughout a substantial proportion of the mappable genome (MacQuarrie ct aI., 
2011). Such findings suggest that, for certain factors, it could be important to re-consider 
data on DNA binding from older experiments that did not have high-throughput approaches 
available. 
We have recently performed ChIP-Seq for the myogenic regulatory factor (MRF) 
MyoD in murine cells of the skeletal muscle lineage, and described widespread binding of 
MyoD both in intra- and intergenic regions of the genome (Cao et aI., 2010). MyoD is a 
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member of the basic helix-Ioop-helix (bHLH) family of transcription factors, a large group of 
factors that all possess a basic region that permits DNA binding and amphipathic helices that 
permit dimerization with other bHLH family members (Lassar et al., 1989; Murre et al., 
1989). In myogenic cells, MyoD heterodimerizes with members of the E-protein family of 
bHLH proteins, binds DNA in a sequence specific fashion, and leads to target transactivation 
(Lassar et al., 1991). We found MyoD bound extensively both in undifferentiated, 
proliferating myoblasts, as well as in terminally differentiated myotubes. Genes that had 
increased expression with differentiation were associated with MyoD ChIP-Seq peaks that 
increased during differentiation, and genes that decreased expression were associated with 
decreasing MyoD peaks. Analysis of the neighboring areas to MyoD bound sites revealed 
potential binding sites for a variety of other factors that are known or believed to play roles 
during myogenesis (eg. ApI, Meis, RullX, Spl). 
Rhabdomyosarcoma (RMS) is a pediatric tumor of skeletal muscle that resembles 
cells of the myogenic lineage both at the level of molecular markers, as well as morphology 
(Merlino and Helman, 1999; Sebire and Malone, 2003). Puzzlingly, the tumors routinely 
express MyoD, even though expression of that factor is normally sufficient to cause terminal 
differentiation of the skeletal muscle cells it is expressed in. Previous work identified no 
defect in the ability of MyoD in RMS to bind to DNA, but rather in its ability to activate 
myogenic target genes (Tapscott et al., 1993), but the binding ofMyoD in these tumors has 
never been investigated in a genome-wide fashion. 
We have also recently identified multiple transcriptional inhibitors of myogenesis as 
being present in RMS, including the bHLH factor MSC (or MyoR) (Yang et al., 2009). MSC 
has been shown to also heterodimerize with E-proteins and bind E-boxes in vitro (Lu et al., 
1999), and in RMS, it inhibits myogenic activity. Numerous bHLH myogenic inhibitors 
have been described (reviewed in (Berkes and Tapscott, 2005)), but the extent of their 
binding throughout the genome and their relation to MyoD binding has not been explored 
directly. While it is possible that individual inhibitors could bind at a small subset of sites 
bound by MyoD and have a relatively direct relationship between binding and inhibitory 
function, it is also possible that, as with MyoD, inhibitors could bind at an excess of sites 
compared to those they act at directly. 
62 
To address these two questions, the relation of MyoD binding in RMS to normal 
myogenic cells, as well as a direct comparison of a myogenic bHLH inhibitor to MyoD, we 
have performed ChIP-Seq for I) MyoD in an embryonal cell culture model ofRMS, RD 
cells; 2) MyoD in primary human myoblasts and myotubes; 3) MyoD in human fibroblasts 
converted to differentiated myotubes through viral expression of MyoD; and 4) MSC in RD 
cells. We have found that MyoD binds widely throughout the genome ofRD cells and, 
surprisingly, MSC binds at a comparable number of sites. MyoD and MSC exhibit both 
unique and overlapping binding sites, a pattern paliially driven by sequence preference, 
suggesting a complicated functional interplay between the two factors. Comparison of 
MyoD binding between RD cells and normal human myotubes identifies many shared 
binding sites, but specific differences with potential functional implications. These 
differences include a different proportion of MyoD-favored E-boxes bound by MyoD in each 
cell type, as well as differences in the motifs for potential cooperative myogenic factors 
adjacent to MyoD-occupied sites. One of the binding motifs identified is that of RUNXI , a 
factor capable of differentiating RlY1S cells when expressed exogenously in them, 
demonstrating the potential therapeutic implications of these differences between cell types. 
Results 
MSC binding in RD cells 
ChIP-Seq of endogenous MSC and endogenous MyoD in RD cells was performed to 
explore the role of MSC in the tumor cells, as well as to compare the binding profile of one 
of the many myogenic bHLH inhibitors to MyoD itself. Somewhat surprisingly, MSC binds 
at a comparable number of sites throughout the genome as does MyoD (Table 3.1). 
Biologically independent site-specific ChIPs were performed and confirmed a selection of 
MyoD and MSC-specific bound locations identified by the ChIP-Seq as being specifically 
enriched by the appropriate antibody (Fig 3.1). 
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Motif analysis of all MSC-bound sites in the genome identifies a preferred binding 
site very similar to MyoD, with MSC preferring a GC E-box with an additional 3' flanking 
'G', giving a binding site of CAGCTGG (Fig 3.2A). Overlap analysis of p-value ranked 
sites was performed to compare MyoD to MSC in RD cells, and identified a surprisingly high 
overlap, suggesting that MSC binds at many of the same sites throughout the genome as 
MyoD (Fig 3.2B). Examination of screenshots from the ChIP-Seq data demonstrates that 
there are sites bound only by MyoD or by MSC, sites that bind both factors in an apparently 
identical pattern, as well as closely overlapping binding patterns (Fig 3.2C). Bound sites 
specific for MSC are enriched for GC E-boxes with specific flanking nucleotides, giving a 
preference for CCAGCTGG (Fig 3.2D), a binding site that, given its completely palindromic 
nature, may possibly indicate a homodimer binding site. Electrophoretic mobility shift 
assays confirmed the ChIP-Seq motifs, with MSC binding to the CCAGCTGG site strongly, 
either as a homo- or heterodimer, and MyoD binding poorly (Fig 3.3, lanes 1 - 4). Inversion 
of the flanking nucleotides to give GCAGCTGC resulted in a restoration of MyoD binding, 
while still pennitting MSC binding, though possibly at a slightly reduced level (Fig 3.3, 
compare lanes 4 and 8 and 3 and 7). 
The overlap in binding between MyoD and MSC is substantial, but the distribution of 
bound locations shows some differences. All the sites bound by MyoD and MSC in RD cells 
were grouped into categories based on their relationship to annotated genes. While the 
distribution of MyoD and MSC peaks in introns, intergenic areas, the 3' end of genes and 
areas farther up- or downstream of gene bodies appear basically identical for MyoD and 
MSC, MSC peaks are more abundant in promoters and the exons of gene bodies (Fig 3.4). 
We have previously reported the use of tandem affinity purification coupled to LC-
MS/MS (liquid chromatography tandem mass spectrometry) to identify the protein 
complexes that MyoD and E-proteins form in RD cells (Yang et aI., 2009), and the same 
technique was performed in RD cells using tagged MSC. Tagged MSC was tested for 
functionality and binding and was found to both repress myogenic reporters and bind E-
boxes in vitro with a comparable pattern to untagged MSC (Fig 3.5). LC-MS/MS identified 
a relatively small number of proteins as associating specifically with MSC (Table 3.2). MSC 
associates with all of the E-proteins with a high coverage rate of their sequenees and, in 
agreement with our findings with tagged MyoD, does not appear to associate directly with 
MyoD, offering further evidence that our ChIP-Seq data represents distinct MyoD- and 
MSC-containing complexes bound to DNA. 
MyoD binding in human myoblasts and myotubes and human rhabdomyosarcoma cells 
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ChIP-Seq was performed for endogenous MyoD in 1) the embryonal cell culture 
model ofRMS, RD cells; 2) primary human myoblasts and myotubes; and 3) human foreskin 
fibroblasts (HFFs) converted to myotubes via the expression ofMyoD from a lentivirus, 
using polyc1onal antibodies specific to MyoD that have been previously described (Tapscott 
et al., 1988). In agreement with our findings in normal myogenic cells of murine origin, 
MyoD peaks, indicating bound MyoD, were at thousands oflocations throughout the human 
genome in both myoblasts and myotubes, either those created from fibroblasts, or from 
primary cells. Also, as would be predicted from the aforementioned finding that the D::'-JA 
binding of MyoD in rhabdomyosarcoma cells is not impaired, a comparable number of 
MyoD-bound sites were found in RD cells as in the primary human myoblasts and myotubes 
at a variety ofp-value cutoffs (Table 3.1). HFFs had considerably more peaks at all cutoffs 
compared to any other cell type, presumably due to the overexpression of the lentivirally 
expressed MyoD binding to low-affinity MyoD sites in significant quantities (Y. Cao, Z. 
Yao, unpublished observations). In all cases, MyoD binds throughout the genome, with 
comparable proportions bound in all genomic areas examined (eg. promoter, introns, 
intergenic) (Fig 3.6). 
The p-value ranking of MyoD-bound sites was used to rank sites and then examine 
the extent of overlap in specific MyoD peaks between different cell types and conditions, 
therefore identifying the extent to which MyoD binds at identical locations in the two 
compared conditions. Occupied sites in HFF+MyoD cells showed considerable overlap with 
occupied sites in myotubes from primary cells (Fig 3.7 A), with myotubes of either type 
showing a somewhat reduced overlap with occupied sites in primary myoblasts (Fig 3.7B). 
Comparison of the overlap between RD cells and myoblasts and myotubes showed that in the 
primary human cells, more MyoD-bound sites were shared between myotubes and RDs than 
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myoblasts and RDs, and the overlap between HFF+MyoD cells and RDs was comparable to 
that seen with the primary myotubes (Fig 3.7C). We have previously proposed that RMS 
represent an arrested transitional state between myoblasts and myotubes, with expression of 
certain cellular factors reminiscent of normal cells going through that transition, and the 
similarity of the MyoD binding pattern to the myotube binding supports that model. 
MyoD binding in RMS cells and primary human cells dfffers at a subset of sites with 
potential functional implications 
Given the overall high degree of similarity in bound MyoD locations between RMS 
and non-tumor cells, and the finding that RUNXl and RP58 can differentiate RMS, we 
hypothesized that comparison of MyoD peaks between myotubes and RD cells would reveal 
subtler, but potentially functionally important, differences in bound sites and potential co-
factors. To address this issue, we first examined the sequence specificity of the E-boxes 
bound by MyoD in RDs and in myotubes. We have previously shown that the majority of 
MyoD in blasts and tubes in murine cells are bound at E-boxes with either a central 
dinucleotide of GC or GG (Cao et aI., 2010), translating to E-boxes with either the sequence 
CAGCTG or CAGGTG. In the comparison in human cells, RDs exhibit a shift in those 
specific E-boxes relative to the primary human myotubes, with a relatively higher proportion 
ofGG E-boxes and a relatively lower proportion ofGC E-boxes (Fig 3.8A). Since MyoD 
binds in a heterodimer with E-proteins to E-boxes, but the relative affinity of all the possible 
MyoD:E heterodimers for specific E-boxes is unknown, this suggests that there may be a 
difference in one or more MyoD:E heterodimers in RMS. RT-PCR for each of the E-
proteins, as well as some specific isoforms of them, demonstrates that myotubes express 
dramatically different levels of some E-proteins compared to RD cells (Fig 3.8B). 
To address the question of whether RMS exhibit a difference in factors that cooperate 
to regulate myogenesis, we performed a motif analyses to look for positively or negatively 
em-iched sequence motifs adjacent to MyoD peaks. The analysis compared the MyoD peaks 
found specifically in primary human myotubes to those in RD cells, to determine if any 
motifs would be found that could explain the difference between the cells. Interestingly, the 
analysis identified the binding site for the mnt-related transcription factor RUNXl as 
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enriched adjacent to primary myotube-specific peaks, a finding in agreement with the data 
presented in Chapter 2 (Fig 3.8e, row 1). The analysis also found potential binding sites for 
a nuclear factor (NFIC) that been proposed to cooperate with bHLH proteins in myogenic 
cells (Hebert et al., 2007) (Fig 3.8e, row 3), and the binding site for a JUN protein (Fig 
3.8e, row 2). In agreement with the results of the E-box analysis mentioned above, the 
motif analysis identified a depletion of GG core E-boxes in RD cells relative to myotubes 
(Fig 3.8e, row 7). 
Discussion 
MSC was initially described as a myogenic inhibitor with the ability to bind E-boxes 
and repress both myogenic reporters and the process of MyoD-mediated myogenic 
conversion (Lu et al., 1999). MSC knock-out mice were found to have no discernable 
phenotype however, until crossed with knock-outs for the MSC homolog, capsulin, leaving it 
an open question on how many gene targets are strongly affected by MSC activity (Lu et al., 
2002). In the nervous system, another transcriptional repressor, termed NRSF, was found by 
ChIP-Seq to be bound at a more restricted number of sites (~2000), and seems to have a 
relatively direct relationship between binding and activity (Johnson et al., 2007). In stark 
contrast to that, MSC binds throughout the genome, and shares a surprisingly large number 
of bound sites with MyoD itself, suggesting that it is not the relatively simple situation of 
MSC binding at some subset of MyoD targets to regulate them. The results with the favored 
binding motifs suggests that sequence accounts for some of the difference in binding, 
especially MSC-specific sites, but the exact relationship between the ability to bind in vitro 
and the locations that are actually bound in vivo will likely require further investigation of the 
influences exerted by both chromatin accessibility and cooperative factors to be explained 
completely. Similarly, the greater presence of MSC peaks in promoters and exons of genes 
may have functional implications, but factors such as GC-content will need further 
investigation to determine if they account for the observed differences. While we initially 
identified MSC in the RD cells by LC-MS/MS using tagged E2A, the mass spectrometry 
results with tagged MSC indicate it associates with all of the E-proteins. Relative binding 
affinities and sequence preferences will need to be determined for the various MyoD-, MSC-
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and E-protein dimer combinations to better understand the relationship between them and the 
functional implications. 
The genome-wide binding ofMyoD in RD cells agrees completely with our prior 
findings that MyoD activity is compromised in RMS, but its DNA binding itself is generally 
unaffected. Our findings with the ChIP-Seq now expand these conclusions in two respects: 
1) they demonstrate that, as we have previously proposed, RMS cells appear to be perched on 
the verge of terminal differentiation, and 2) while MyoD binds widely throughout the 
genome, there are detectable differences in both the sequence of the E-boxes it binds and the 
potential adjacent binding sites for other factors. Such differences that would be likely to 
affect MyoD functionality are of special interest, as they may suggest ways to rescue the 
differentiation defect in RMS. 
The fraction of bound MyoD across various genomic locations is almost 
indistinguishable between the RD cells, primary cells, and converted fibroblasts. The p-
value ranked analysis of bound locations shows that, while the general pattern of binding is 
consistent, the similarity in bound sites is higher between the myotubes and RD cells than 
between myoblasts and RDs, as would be predicted by our model, and our findings with 
miR-206 in Chapter 2. 
The differences in bound E-boxes and motif analysis suggest that there are more 
subtle defects or differences in MyoD binding between RMS cells and human myogenic cells 
that successfully differentiate. Modeling ofbHLH complexes binding to E-boxes CA. Fong, 
P. Bradley, unpublished observations) has suggested that E-proteins bind to the 3' end of the 
E-box, which is the half of the E-box that demonstrates the difference in proportional 
occupation between RDs and myotubes (CAGCTG versus CAGGTG). FUlther experiments 
would need to be performed to detelmine if the differences in E-protein expression correlate 
with differences in their preferred E-box binding sequence when heterodimerized with 
MyoD. If so, it may be that expression a single E-protein could shift the pattern of MyoD 
binding on a wide scale, and possibly lead to terminal differentiation. 
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The functional impact of the motif analysis is clearer than that of the E-box 
composition. The finding that the RUNXI motif is underrepresented near RD specific MyoD 
peaks compared to primary myotubes is in perfect agreement with the finding that RUNXI 
differentiates RMS cells when expressed in them. While the results in Chapter 2 found a role 
for RUNXI in cooperating with MyoD at myogenic targets to increase their expression, it is 
possible that it also serves an additional role by altering MyoD binding, which could explain 
its presence near myotube-specific MyoD peaks. ChIP-Seq for RUNXI in RD cells and 
myotubes could solve that question, as could MyoD ChIP-Seq in RD cells expressing 
RUNX 1. The other motifs identified by the analysis, such as for NFIC, might also be of 
functional significance in RMS, possibly serving as additional mechanisms by which the 
cells can be driven to differentiation, and representing defective pathways in the tumors. 
Materials and Methods 
Chromatin immunoprecipitation 
ChIP was carried out as described in Chapter 2. ChIP-Seq was performed as has been 
described previously (Cao et aI., 20lO), with antibodies as listed in Chapter 2. The primer 
sequences for the MyoD and MSC-specific sites checked for independent ChIP-Seq 
confirmation are as follows: A gcttgatgatgcttgcagaa, cggagaggatcatgtaactgc; B 
ctggtccctttcaggagaca, gccgtccatctaaaggtcaa; C aatgacaagcactcgcacaa, atcgagaagttgcgtgcttt; 
D - atctggaatgccttctgtgg, attgcctaggaagggacaca; E - gcgacgagctccacatctac, 
aggatgcccatgactttgag; F ctcaccatccgaccaagagt, ggggtcacgtgtgtatgaga. Real-time was 
performed using Sybrgreen, as in Chapter 2, and relative enrichment calculated as % of Input 
in samples with antibody/% ofInput in samples with no antibody. 
Electrophoretic mobility shift assays 
Electrophoretic mobility shift assays were performcd as described in Chapter 2. 
Probe sequences were as follows (forward probes only listed): Probe 1: 
CGGCCGACCAGCTGGAGATCCT; Probe 2: CGGCCGAGCAGCTGCAGATCCT; 
Probe B 1: GATCCCCCCAACACCTGCTGCCTGA. Complexes were resolved on 6% 
polyacrylamide gels and exposed to radiographic film. 
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Motif analysis 
Motif analysis was performed as in (Cao et aI., 2010). 
RT-PCR 
RT-PCR was performed as in Chapter 2, on cDNA prepped from total RNA isolated 
using the RNeasy mini kit (Qiagen) from RD cells transduced with an empty retroviral 
construct and placed in differentiation media for 24 hours after selection or from human 
fibroblast cells expressing an estradiol-inducible MyoD (MyoD-ER), and placed in 
differentiation media with 10-7 M beta-estradiol for a period of 96 hours. Primers were as 
follows: CCAACTTCTTTGGCAAGTGG, TCTCCATAGTTCCTGGACGG; 
HEBisoA +B: GACCAACTACACTGGGAAGCA, GGAAGGACTTGGTTGACCACT; 
HEBisoC: TGCTT ATCCTGTCCCTGGAA, ATCTGAATTTGGGGATGGTG; E 12: 
GTGACATCAACGAGGCCTTT, AGTTTGGTCTGGGGCTTCTC; E47: 
GAGGACGAGGAGAACACGTC, GACAGCACCTCGTCCGTACT; TIMM17b: 
GGAGCCTTCACTATGGGTGT,CACAGCATTGGCACTACCTC. 
Protein purification and mass spectrometry 
Five nearly confluent 24.S cm x 24.S cm tissue culture dishes of RD cells stably 
expressing nTAP-tagged MSC were scraped into PBS and spun down at 1100 RPM for S 
minutes. The cell pellet was resuspended in Sx volume of Buffer A (10 rnM Hepes, 1.S llli\1 
MgCh, 10 rnM KCl, SOO uM DTT) with the addition of complete protease inhibitors (Roche) 
and placed on ice for 10 minutes. Cells were spun at 600 g for 10 minutes at 40 then 
resuspended volume Buffer A, then passed through 22G 1112 needles once, then 
2SG 11/2 four times while being kept cold. Cells were spun at lSOOOg for 20 min and 
the upper layer of supernatant and cellular debris removed, taking care to preserve the nuclei 
at the bottom. nuclei were resuspended in Ix volume of Buffer B (20 mM Hepes, O.S 
rnM EDTA, 100 rnM KCl, 10% glycerol, 2 rnM DTT, 3 mM CaCh, 1.5llli\1 MgCh, 0.2S 
mM NaOV03, 10 mM NaF, 50 rnM beta-glycerophosphate) with complete protease 
inhibitors. 2 ul ofthe suspension was quantitated by UV spec for DNA content, and the 
nuclei subjected to MNase digestion for 10 min at 37° (0.25 U ofMNase for every 40 ug of 
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DNA). Cells were then placed on ice, and 20 ul of 0.5 M EDTA added for each 500 ul of 
lysate, and cells rocked at 4° for 1.5 to 2 hrs. Material was then spun at 14000 RPM for 15 
min at 4° and then supernatant saved. Rabbit IgG beads equal to 1110 of the volume of the 
supernatant were added and rocked in the cold for 1.5 to 2 hrs. Beads were spun down 
gently, then placed in a chromatograph column (Bio-rad) and washed with Buffer B Ix as the 
above composition and then 2x with Buffer Bat 150 mM KCl. Beads were then washed 3x 
with TEV buffer (10 mM Hepes, pH 7.6, 150 mM KCl, 10% glycerol, 0.1 % NP40, 0.5 mM 
EDT A, 1 mM DTT). TEV protease (Invitrogen) was resuspended in TEV buffer at 1 U/uL 
then 100 U ofTEV added to each column for every 50 ul of packed beads and the columns 
capped. After 4 hrs sitting at 4°, the cap was removed, the eluate collected and then 3x 
washes of 100 ul each with calmodulin binding buffer (10 mM Hepes-KOH pH 8.0, 150 mM 
NaCl, 1 mM MgOAc, 1 mM imidazole, 0.1 % NP-40, 2 mM CaCb, 10 rnM beta-
mercaptoethanol) done over the beads and combined with the eluate. 1 M CaCl2 was added 
at 1/250th of the volume and mixed by inversion. 100 ul of calmodulin sepharose beads 
(Stratagene) were added and rocked in the cold for 1.5 hrs. Beads were spun down, placed 
on the chromatograph column, rinsed 2x with 1 mL of calmodulin binding buffer, then 2x 
with 1 mL of calmodulin rinsing buffer (50 rnM Amm. Bicarb. pH 8.0, 75 rnM NaCl, 1 mM 
MgOAc, 1 rnM imidazole, 2 mM CaCb). Complexes were then eluted with a total of 6x 100 
ul rinses of calmodulin elution buffer (50 mM Amm bicarb pH 8.0, 25 mM EGTA). Elution 
was then taken to the Fred Hutchinson Protein Core Facility for trypsinization and subjected 
to LC-MS/MS. 
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Table 3.1 Number of identified ChIP-Seq peaks in human cells at specific p-values. 
p-value 
ChIP 1.00E-05 1.00E-07 1.00E-1O 
RD.MyoD 52762 36267 25231 
RD.MSC 57002 39868 26392 
10 Myoblasts 44364 32313 23158 
10 Myotubes 58449 43334 31630 
HFF+MyoD 131203 111313 73284 
Table 3.2 Proteins identified b LC-MS/MS as associated with MSC in RD cells. 
Protein S 'mbol 
TDP43 (A4GUK4) 
ARHGEFI0 
CERKL 
EBF3 
gil14783413lhypothetical_prot 
HlSTlH2AE 
HIST2H2BE 
HMGA2 
HNRPC 
HNRPH1 
HNRPM 
HRNR 
HSPA8 
IPI00221261 
KRTl4 
KRT2 
LDB2 
MATR3 
OTTHUMP00000028832 
PBX2 
PRKDC 
MSC (Q53XZ2) 
RBMX 
SNRPE 
TCF12 (HE B) 
TCF3 (E2A) 
TCF4 (E2-2) 
1 
1 
2 
1 
2 
2 
2 
2 
3 
1 
5 
1 
2 
1 
1 
1 
11 
21 
13 
2 
1 
2 
6 
2 
22 
23 
21 
5 
4 
4 
3 
7 
2 
3 
10 
3 
2 
7 
1 
5 
4 
17 
29 
40 
34 
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* # of Unique peptides lists the number of distinct peptides belonging to the indicated protein 
determined by the MS analysis to be present in the sample. 
** Percent of A.A.'s indicates the percentage of the total number of amino acids in each 
identified protein that are actually detected in the MS data. 
Bold entries indicate known transcription factors. 
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Figure 3.1. Validation of MyoD and MSC ChIP-Seq results. A) ChIPs on biologically 
independent RD samples were performed using anti-MyoD antibody and anti-MSC antibody 
as for the ChIP-Seq. Individual loci to be tested were chosen based on the ChIP-Seq 
identifying them as having a strong, MyoD-specific enrichment. B) ChIPs were perfOlmed 
for MSC and individual sites tested as for lA, only with MSC-specific sites being chosen for 
this set ofloci. C) ChIPs for MyoD and MSC were tested using primers for a gene that is not 
expressed in RD cells and should be essentially lacking any MyoD or MSC signal, according 
to the ChIP-Seq. All values are represented as the 'relative enrichment', which is calculated 
as % ofInput with antibody/% ofInput without antibody using qPCR. 
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Figure 3.2. DNA binding characteristics of MSC in RD cells. A) The binding motifs of 
MSC and MyoD in RD cells show a preference in both instances for a central GC 
dinucleotide, but MSC favors an additional G at the + 1 position compared to MyoD. B) 
MyoD and MSC ChIP-Seq peaks were ranked based on p-value and the proportion of 
identical peaks at various p-values determined and graphed as indicated. Colors approaching 
closer to blue indicate a higher proportion of identical peaks. C) Select UCSC Genome 
Browser screenshots from the MyoD and MSC ChIP-Seq data show genomic locations with 
either specific binding of one or the other factor, apparently identical binding by both factors, 
or slightly offset binding of the factors. The x-axis indicates DNA position, the y-axis 
indicates the number of sequencing reads found at those locations, and the position of E-
boxes are represented by small black marks at the bottom of each panel. D) A DNA binding 
motif analysis similar to what was done in 2A, but this time comparing peaks found 
specifically in the MSC sample to peaks shared between MyoD and MSC. 
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Figure 3.3. Binding preferences identified by ChIP-Seq are reflected in in vitro DNA 
binding assays. Electrophoretic mobility shift assays were performed to determine if the 
MSC specific binding site identified in Figure 2D correlated with any observable differences 
in DNA binding. In vitro translated proteins were mixed alone and together as indicated with 
either of two radioactive probes, differing only in which side the E-box-flanking C and G 
were present on. 
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Figure 3.4. Genomic distribution of MyoD and MSC binding. All MyoD and MSC 
peaks in RD cells were examined to detemline which ofthe indicated, non-mutually 
exclusive categories they fell under. The fraction of peaks that qualify as each category are 
graphed on the y-axis. Promoter: +/-500 bp from thc transcription start (TSS); Prox 
promoter: +/-2 kb from the TSS; 3 prime: +/-500 nt from the end of the transcript; upstream: 
-2 kb to -10 kb upstream of the TSS; downstream: +2 kb to + 1 0 kb from the end ofthe 
transcript; intergenic: > 1 0 kb from any annotated gene. 
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Figure 3.5. nTAP-tagged MSC functions like untagged MSC in functional assays and 
DNA binding ofbeterodimers. A) Luciferase assays were performed in C2C12 cells at two 
different time points after transfection with a muscle-specific creatine kinase (MCK) 
luciferase reporter, a beta-galactosidase internal control and constmcts as indicated. Results 
are from a single experiment with each condition performed in duplicate. B) Electrophoretic 
mobility shift assay using proteins as indicated and an E-box containing radioactive probe. 
Note that nTAP-tagged MSC is larger than MSC and is expected to appear at a higher 
location on the exposure. 
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Figure 3.6. Genomic distribution of MyoD bound sites in RD cells compared to human 
myohlasts and myotuhes. As in figure 3.4, the fraction of MyoD peaks in each indicated 
genomic region is graphed for primary myoblasts (10 MB), primary myotubes (10 MT), 
fibroblasts converted to myotubes by MyoD (HFF +MyoD), and RD cens (RDs). 
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Figure 3.7. The sites bound by MyoD in RD cells overlap to a larger extent with sites 
bound by MyoD in myotubes than in myobJasts. A) MyoD peaks were ranked based on p-
value, and then the proportion of identical peaks between human myotubes from primary 
samples and from MyoD-expressing fibroblasts. The percentage of identical peaks was 
calculated at various cut-off points by rank, as indicated by the y-axis values. As the 
proportion of identical peaks increases toward one, the color shades further to blue. B) The 
extent of identical MyoD peaks is visibly lower between either HFF+MyoD cells or primary 
human myotubes and the primary human myoblasts, regardless of peak p-value cut-off. C) 
The same analysis was performed as in A and B, but comparing MyoD peaks in RD cells to 
MyoD peaks in either of the two types ofmyotubes or in primary myoblasts. 
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Figure 3.8. Human myotubes have a subset of MyoD-bound sites that differ from the 
sites bound in RD cells with potential functional differences. A) MyoD peaks found 
specifically in primary human myotubes were compared to those found specifically in RD 
cells, and the composition of E-boxes under those peaks determined and quantified. 
CAGCTG and CACCTG are the favored MyoD bound E-boxes. B) RT-PCR for various E-
proteins and specific isoforms of the E-proteins in RD cells cultured in low-serum 
differentiation media and human fibroblasts converted to myotubes through the action of an 
estradiol·inducible version ofMyoD. HEB iso A+B and iso C refer to different isoforms of 
the E-protein, HEB. TIMM17b is an internal control. C) Primary human myotube specific 
MyoD peaks were compared to RD specific MyoD peaks and an analysis performed on the 
DNA immediately (± 100 basepairs) surrounding the peaks to determine over- and under-
represented DNA motifs. Motifs were compared to a transcription factor database to 
determine what DNA binding factor likely accounts for the discovered motif (DB match, DB 
e-value, DB logo). 
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Summary 
The binding of transcription factors to specific DNA target sequences is the 
fundamental basis of gene regulatory networks. Chromatin immunoprecipitation combined 
with DNA tiling arrays or high-throughput sequencing-ChIP-chip and ChIP-Seq-has 
produced many recent studies that detail the binding sites of various transcription factors. 
Surprisingly, data from a variety of model organisms and tissues have demonstrated that 
transcription factors vary greatly in their number of genomic binding sites, and that binding 
events can significantly exceed the number of known or possible direct gene targets. Thus, 
our current understanding of transcription factor function must expand to encompass what 
role, if any, binding might play outside of direct transcriptional target regulation. 
The finding, in both normal models of myogenic differentiation and in 
rhabdomyosarcoma cells, that MyoD binds at many thousands of places throughout the 
genome beyond its direct targets suggests that the models of transcription factor binding 
leading directly to nearby gene regulation are not adequate. We propose alternate 
possibilities that could account for the genome-wide binding observed for certain 
transcription factors, both myogenic and non-myogenic. The alternate, non-exclusive, roles 
that we discuss include action at a distance, large-scale chromatin remodeling, the site 
accessibility model, and the selective advantage model. The novel model we propose, the 
selective advantage model, hypothesizes that widespread genome binding of certain 
transcription factors offers an evolutionary advantage. If factors bind throughout the 
genome, then a single mutation in that factor can affect numerous downstream targets in a 
single step, rather than requiring iterative alterations or additions of binding sites. While the 
models proposed here are speculative, they give a framework in which to consider further 
large-scale data on transcription factor binding. 
Regulatory networks and the core model of gene regulation 
The complex interactions between multiple transcription factors and gene targets 
across various tissues, cellular contexts, and time points are termed 'transcriptional 
regulatory networks'. It has been stated that a truly thorough understanding of sueh 
interactions should theoretically explain how an organism is 'computed' from its DNA 
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(Weintraub, 1993). The core model of gene regulation posits that transcription factors recruit 
a polymerase complex to the transcriptional start site (ptashne and Gann, 2002). 
Transcription factors initiate this by binding at nearby or distant DNA sequences and directly 
interacting with components of the polymerase complex or with complexes that indirectly 
mediate the polymerase interaction. In eukaryotes, the latter may include chromatin 
remodelers or modifiers that facilitate access or increase protein-protein affinities via histone 
modifications (Cosma, 2002; Fry and Peterson, 2001). The simplest view of the core model 
would suggest that factor binding directly correlates with transcriptional regulation. 
However, numerous examples of the separate regulation of factor binding and transcriptional 
activation suggest otherwise (Davis et al., 1990; Guarente et al., 1982; Turcotte and 
Guarentc, 1992). For example, recent studies indicate that the sequence of the DNA binding 
site can induce conformational changes in the bound transcription factor that pennits 
transcriptional regulation by subsets of a transcription factor family that can bind to similar 
sites (Leung et al., 2004; Meijsing et al., 2009). 
Defining the relationship between transcription factor binding and target regulation 
across the entire genome of various species has become an attainable goal with the recent 
explosion in advanced computing and information processing tools. These advances have 
resulted in some remarkable progress in reconstructing and predicting regulatory networks 
(Lee et aL, 2002). The advent of ChIP-chip (chromatin immunoprecipitation coupled to 
microarray hybridization) and ChIP-Seq (chromatin immunoprecipitation coupled to high-
throughput sequencing) have now allowed for determination of the precise, genome-wide 
distribution oftranscription factor binding sites. The results of numerous studies employing 
these techniques have been at times predictable and at other times surprising. While some 
studies have shown the expected correlation between factor binding and gene regulation, 
others have observed binding events that vastly exceed the number of expected gene targets 
(Table 4.1). Given these findings, it is timely to reconsider the relationship between 
transcription factors and gene regulation and the role, if any, that widespread transcription 
factor binding may play outside of direct gene target regulation. 
Transcriptional Regulatory Networks 
Transcription factors interact in a sequence-specific fashion with DNA to either 
increase or decrease transcription of gene targets. Transcription factors often bind and 
regulate multiple simultaneously, and targets, in turn, are frequently regulated by 
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multiple factors. Regulatory networks can be constructed to describe these interactions, and 
represent the interactions that occur at multiple factor-target levels. Networks can be 
comprised of various motifs, which represent the regulatory approaches taken by one or more 
factors at specific Multiple types of motifs have been described, but two common 
ones include the feed-forward loop and multi-input motif (Fig 4.1). Using these and other 
commonly found motifs (eg. auto-regulatory loops in which a gene product downregulates its 
own production), transcription factors are able to establish complex and dynamic 
mechanisms of gene regulation. 
Transcription Factor Binding and Direct Gene Regulation 
Several genome-wide transcription factor binding studies in various model organisms 
have supported a relatively direct connection between factor binding and gene regulation. 
One of the first genome-wide assessments of transcription factor binding in yeast reported 
transcription factor binding in promoter regions, in spite of the presence of binding motifs in 
both coding and intergenic regions (Lieb et al., 2001). Another report evaluating over 100 
tagged factors in yeast identified more than 4,000 promoter-transcription factor interactions 
and described numerous regulatory circuits (Lee et aL, 2002). The subset of circuits that 
comprised feed-forward networks (Fig 4.1A) alone was extensive, involving 39 factors, 49 
distinct networks, and greater than 10% of all bound areas. This study emphasized both the 
importance of regulatory networks in controlling gene expression, as well as the ability of 
ChIP studies to uncover such networks. 
A later study looking at an individual transcription factor in yeast, with roles in both 
filamentous growth and mating behavior, also found that DNA binding tightly correlated 
with function. Under cellular conditions that activated either growth or mating functions 
individually, the factor was found to occupy approximately 60 unique binding sites that were 
located in the promoters of genes with appropriate corresponding functions (Zeitlinger et al., 
2003). This binding was noted to be dependent on another transcription factor for the 
process of filamentation, an example of the importance of cooperative factor binding (Fig 
4.1B) in mediating transcription factor activity. 
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The forkhead box A homolog pha-4 regulates organogenesis of the pharynx in C. 
elegans, and provides an example offactor binding correlating closely with direct gene target 
effects in a multicellular organism. Initial studies demonstrated that expression of its targets 
correlated with PHA-4 binding sites in promoter regions, and that the timing oftarget 
expression correlated with binding affinity between transcription factor and its target 
sequence (Gaudet and Mango, 2002). Follow-up studies refined this model, providing 
evidence for other factors that cooperated with PHA -4 binding to modulate timing of target 
expression (Gaudet et al., 2004). Taken together, the data suggested that pharyngeal organ 
development is regulated by a combination of PHA-4 binding affinity and cooperating 
factors to temporally regulate gene expression. It also suggested that it should be possible to 
predict the time of expression of a putative pha-4 target gene solely from analysis of its DNA 
sequence. 
Recent ChIP-seq data for pha-4 has been in agreement with this assessment. The 
great majority (>90%) of the bound sites identified in either embryos or larvae can be 
designated as 'gene-associated' using a distance cut-off of 2 kb or less between a bound site 
and nearest gene (Zhong et al., 2010). Overlapping the binding with gene expression data 
(high-throughput sequencing of RNA), most (87%) of the associated genes were expressed 
when PHA-4 binding was present, and a decrease in factor binding was associated with a 
reduction in expression for most (60%) presumptive targets, suggesting that binding of the 
factor activated the expression of those genes. 
Studies in Drosophila melanogaster have identified the importance of cis-regulatory 
modules (CRMs), short DNA sequences (~300-500 nucleotides in length) that integrate 
multiple input signals to control gene expression. For example, the binding of Mef2, an 
important factor in mesodermal development, changes temporally during the course of 
muscle development (Sandmann et al., 2006). At the time points evaluated, different factor 
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motifs were noted at Mef2 binding regions, suggesting a cooperative factor mechanism used 
to temporally regulate the expression of various Mef2 Further complexity in 
regulation is also suggested by a study comparing the binding profiles of Mef2 and lameduck 
(Lmd) (Cunha et al., 20 10). Mutants of Mej2 and Lmd demonstrate a similar defect in 
myoblast fusion, suggesting similar or overlapping biological roles; however, while their 
DNA binding profiles overlap significantly, the effect of binding is widely variable. 
Depending on the enhancer target, co-binding can lead to additive, synergistic, or repressive 
effects, as demonstrated in reporter assays using eight different characterized enhancers. For 
example, co-expression of Lmd and Mej2 activates the blow enhancer while expression of 
Lmd counteracts the positive effect of Mej2 on the CG9416 enhancer. While these results 
reveal the potential complexity of regulatory networks, a relatively direct relationship can 
still be inferred between DNA binding and target gene effects. 
The close relationship between DNA binding and gene effect has also been 
observed in mammalian systems. In one of the first studies to use ChIP-Seq, the binding of 
the zinc-finger protein neuron-restrictive silencer factor (NRSF) was mapped to only ~2000 
sites in the human genome (Johnson et al., 2007). It was found that a few hundred potential 
target genes showed relatively 'low' gene expression compared to average cellular transcript 
expression when a NRSF peak was located nearby kb), that NRSF was 
exerting its transcriptionally repressive effects at those genes when bound nearby. Studies of 
other factors, such as Pregnane X receptor (PXR) (Cui et al., 20 I 0) and calcium-response 
factor (CaRF) (Pfenning et al., 2010), have also demonstrated a direct correlation offactor 
binding with gene regulation in mammalian cells. 
Transcription :Factor Binding in Excess of Known Direct Targets 
In contrast to the model of direct gene regulation, several studies have demonstrated 
transcription factor binding at a large number of sites, many of which cannot be clearly 
connected with target gene regulation. In Drosophila, several ChIP-chip studies using whole 
genome tiling arrays have been performed for developmental transcription factors (Li et al., 
2008; Zeitlinger et al., 2007). These studies have identified a large number of binding 
regions, on the order of several thousands, for individual factors in the developing embryo, 
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indicating a greater amount of DNA binding by developmental factors than had been 
anticipated. For example, over 2,000 binding regions were observed for Twist in the 
Drosophila genome in two separate studies utilizing distinct microarray designs (Sandmann 
et al., 2007; Zeitlinger et al., 2007), vastly exceeding the number of known Twist targets and 
including many intronic and intergenic sites. Also unexpectedly, Twist binding overlaps 
significantly with both Dorsal and Snail binding sites, and many of these sites possess highly 
conserved motifs. Their conservation suggests they are likely to be functional sites, but the 
significance ofthem is still unclear. 
While widespread binding of early developmental transcription factors is perhaps not 
entirely surprising (Liang and Biggin, 1998), the unexpected finding has been the 
identification of numerous binding sites of unclear function, including for other factors as 
well. Studies of the binding and gene regulation ofMyc and other proteins ofthe dMax 
family in Drosophila and human cells have shown extensive binding across the genome, but 
that binding did not necessarily correlate with transcriptional regulation ofthe nearby target 
genes (Fernandez et al., 2003; Orian et al., 2003). 
In an early ChIP-seq study examining the interferon-y (IFN-y) responsive 
transcription factor STATl in human cells, a strikingly large number of bound sites was 
observed (Robertson et al., 2007). In unstimulated cells, over 10,000 binding sites were 
identified, and this increased more than four-fold after stimulation with IFN-y. In both 
conditions, approximately 50% ofthe total sites were intragenic and 25% intergenic. While 
there was a strong overlap with sites of known STATl activity, the majority of binding sites 
were not located adjacent to STATl regulated genes, suggesting that many, or most, bound 
sites were not directly regulating a nearby gene target. The authors suggested that many of 
the STATl sites might correspond to weaker, less favored binding sites, or possibly 
functional sites with ST A Tl bound in only a subset ofthe total cell population. 
As another example of widespread binding, the hematopoietic factor GATAI was 
reported to have over 15,000 DNA binding sites in a mouse erythroblast line (Cheng et al., 
2009). GAT AI-factor binding is apparently necessary for the binding of another 
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hematopoietic factor, the basic helix-loop-helix (bHLH) factor Tall, to an adjacent E-box 
motif, the consensus binding site for bHLH factors. There is a strong association of Tall 
binding with erythroid gene regulation (Frankel et al., 2010; Kassouf et al., 2010; Palii et al., 
2011), with over 2000 genes, most of which (90%) were categorized as related to erythroid 
development, having Tal1 binding within putative regulatory elements in one study, and over 
half of Tall-regulated genes containing Tall bound within a proximal or distal regulatory 
element in another study (PaW et al., 2011). In this case, the widespread binding of GAT A 1 
might be identifying the sites that can be bound by Tall, and possibly other factors at 
different times or in different cells, to execute cell-type specific programs of gene expression. 
The myogenic bHLH factor MyoD is another transcription factor that offers potential 
insight into genome-wide binding. MyoD directly regulates genes expressed during skeletal 
muscle differentiation (Bergstrom et a1., 2002) and orchestrates a temporal pattern of gene 
expression through a feed-forward circuit (Penn et aL, 2004). ChIP-seq on MyoD in skeletal 
muscle cells identified approximately 30,000-60,000 MyoD binding sites (Cao et a1., 2010). 
As anticipated, genes regulated by MyoD during myogenesis had associated MyoD binding 
sites. However, almost 75% of all genes were associated with a MyoD binding site and 
about 25% of the MyoD sites were in intergenic regions. Therefore, the majority of MyoD 
binding events were not directly associated with gene regulation. Although regional 
transcription was not detected at these intergenic sites, MyoD binding was demonstrated to 
induce local chromatin modifications, specifically acetylation of histone H4 that is generally 
associated with active and/or accessible regions of the gcnome. 
Together with the studies discussed above, these findings demonstrate that some 
transcription factors have binding events that are vastly in excess of the genes that they 
directly regulate. The remainder of this review will discuss the possible significance ofthese 
large number of transcription factor binding events that are not directly related to gene 
transcription. One proposed explanation for large-scale genome-wide transcription factor 
binding is the presence of 'non-functional' binding sites that serve no biological purpose (Li 
et al., 2008). Alternatively, it has been proposed that transcription factors may bind to many 
low affinity sites in the genome and contribute to gene expression at levels that are low but 
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sufficient to allow evolutionary conservation, an idea proposed from a large scale ChIP-chip 
study in yeast (Tanay, 2006). Presuming that these sites are functional, other possibilities 
include roles in affecting the functional concentration of factors, induction of chromatin 
looping, changing chromatin and nuclear structure, or the evolution of new transcriptional 
regulatory networks. 
Site Accessibility Model 
It has been suggested that binding sites occurring outside of areas directly involved in 
gene regulation may be 'non-specific,' or random. However, these intergenic sites contain 
the factor-specific binding motifs and have been validated both experimentally and 
statistically, the latter by passing very strict statistical cutoffs (Cao et aL, 2010; Robertson et 
aL, 2007). Thus, it seems more appropriate to conclude that the observed genome-wide 
binding of some transcription factors is a biologically specific event; however, the biological 
role at many of the sites remains largely undetermined. 
Based on the binding of the lac repressor to bacterial DNA, it was suggested that 
genome-wide binding at non-regulatory sites might function to maintain an optimum amount 
of available transcription factor in the nucleus (Lin and Riggs, 1975). In this model, some of 
the transcription factor binding sites that are located in intergenic regions or repetitive 
elements might serve that function, helping to fine-tune gene expression by limiting the 
concentration of unbound factors and preventing binding to sites that need to be regulated by 
co-factor occupancy and cooperative binding. In this model, the genome-wide binding 
serves as a reservoir for factors, sequestering them in a manner analogous to other biological 
buffering systems. 
Some studies provide support for this modeL For example, in the Drosophila studies 
that show binding at thousands of sites in the genome in addition to binding at regulated 
genes (Li et aL, 2008; MacArthur et aL, 2009), higher-affinity binding occurred at regulated 
genes, and lower-affinity binding occurred in regions not regulated by the factors. This is 
consistent with the model that accessible DNA serves as a low-affinity reservoir for 
transcription factors and that these sites are not directly regulating regional gene 
transcription. 
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Other studies provide additional support for the notion that transcription factors will 
bind to any available sites genome-wide. ChIP-seq of 15 transcription factors and regulators 
involved in mouse embryonic stem CES) cell biology demonstrated binding for multiple 
factors at the same 3,583 sites in both promoter and intergenic regions (Chen et aL, 2008). 
Similarly, in Drosophila several of the patterning factors exhibit notable overlap in their 
binding sites, although there is variability in the degree of overlap. And while analyses of 
binding site sequences demonstrate, in general, factor specificity for preferred DNA-binding 
motifs previously identified in vitro, many regions also exist which lack consensus binding 
motifs CLi et aL, 2008). Therefore, some genome-wide binding might reflect factor 
interaction with accessible DNA regions that have not been specifically selected for a role in 
regional gene transcription. 
Although likely correct in many instances, this model does not explain why there is 
an order of magnitude, or more, difference in genome-wide binding for factors with 
equivalently complex binding motifs. As noted above, MyoD has -30,000-60,000 binding 
sites whereas Tall is reported to have ~3,000-6,000 sites in erythroid cells (Cao et aL, 2010; 
Frankel et al., 2010; Kassouf et aL, 2010; Palii et al., 2011). Both are bHLH factors that 
dimerize with an E-protein and recognize the core CANNTG E-box motif. The substantial 
difference in their genome-wide binding, however, suggests that sequence complexity is not 
the only determinant of binding. One possibility is that some factors are more constrained by 
site accessibility than others. MyoD can initiate chromatin remodeling at inaccessible sites 
and can bind independently of other factors, whereas the related bHLH factor Myogenin is 
more constrained to bind to accessible sites (Bergstrom and Tapscott, 2001; Cao et aL, 2006; 
Cao et al., 2010; Penn et al., 2004) and the Tall bHLH factor might require GATAI or other 
factors to bind (Palii et al., 2011). This suggests that the difference in the number of My aD 
and Tall binding sites might, at least in part, reflect their relative ability to make new sites 
accessible for binding and to bind independently of other factors. 
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Chromosome Looping and Changes in Nuclear Architecture 
Another, non-exclusive, model is that intergenic binding sites regulate gene 
transcription at a distance. Chromatin looping provides a mechanism for transcriptional 
control by bringing regulatory elements into proximity with target genes. Chromosome 
conformation capture studies indicate that the interaction of the distant locus control region 
(LCR) with the beta globin gene is required for high-level transcription. Interestingly, this 
interaction is dependent on GATAI acting as an anchor (Vakoc et aI., 2005). Given that 
GATAI binds to over 15,000 sites, it is plausible that some proportion of these may effect 
transcription by inducing chromatin loops. In agreement with this idea, the LCR is necessary 
for globin genes to associate with transeriptionally-engaged pom sites (Ragoczy et aI., 
2006), while other experiments demonstrated the association of hundreds of specific genomic 
loci with the murine globin genes in 'transcription factories' (Schoenfelder et aI., 2010). In 
another specific example of chromatin looping leading to gene regulation, a Wnt-responsive 
enhancer downstream of the Myc gene has been shown to loop to cooperate with as' 
enhancer in a beta-catenin/TCF dependent fashion to regulate Myc expression (Yochum et 
aI., 2010). These studies suggest that genome-wide binding might establish productive long-
range interactions, either by looping to bring distant enhancers together with promoters, or in 
more complex interactions such as the co-regulation found in transcription factories. 
Genome-wide Binding Affecting Global Chromatin and Nuclear Structure 
As noted above, many of the MyoD binding events are not directly associated with 
regional gene transcription, but rather with regional histone modifications associated with 
active or accessible chromatin (Cao et aI., 2010). Genome-wide changes in chromatin also 
occur in response to Myc binding (Knoepfler et aI., 2006). Therefore, a major biological 
role of these factors, and perhaps other genome-wide binding factors, might not be to directly 
regulate transcription, but rather to re-organize the chromatin to make regions generally more 
accessible for factors expressed later in development. Such a role is supported by several 
studies of genome-wide influence on chromatin structure of general regulatory factors in 
yeast (Badis et aI., 2008; Ganapathi et aI., 2010; Hartley and Madhani, 2009). 
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Although it might seem unusual to suggest that some transcription factors have a role 
in regional chromatin organization at some sites and function as typical transcription factors 
at others, these represent two related functions of many transcription factors and it is 
reasonable to imagine that they can be deployed independently. For example, at genes 
transcriptionally regulated by MyoD, MyoD recruits histone acetyltransferases and chromatin 
remodeling complexes prior to mediating transcriptional iniitaition, which often occurs 
following the binding of an additional transcription factor (Aziz et al.; Penn et al., 2004; 
Tapscott, 2005). Therefore, the initial steps of transcription factor-mediated chromatin 
modifications can be distinguished from subsequent steps of transcriptional activation. 
The suggestion that some transcription factors might have a role in regional 
chromatin organization that is independent of regional transcription is reminiscent of CTCF, 
which was originally identified as a transcription factor and is now recognized to have a 
broad role in chromatin organization. CTCF has also been found to have tens of thousands 
of binding sites in human and mouse cells (Chen et al., 2008; Kim et al., 2007). The greatest 
portion of CTCF sites were located in intergenic regions and many were at the border of 
distinct chromatin regions, consistent with a role in demarcating different chromatin domains 
(Barsh et al., 2007; Kim et al., 2007). Furthermore, CTCF binding sites were flanked by 
arrays of well-positioned nucleosomes enriched in specific histone types (H2A.Z) and 
specific histone modifications, suggesting additional roles in broad changes in chromatin 
composition and structure (Fu et al., 2008). 
Related to the model that some transcription factors might influence chromatin on a 
global scale is the idea that some ofthese factors might contribute to other aspects regional 
nuclear organization. Apart from its role in affecting chromatin structure, CTCF may also 
mediate long-range chromatin interactions (Hadjur et al., 2009; Mishiro et al., 2009). Also, 
as previously noted, both MyoD and Myc mediate broad epigenetic reprogramming within 
the nucleus, and it is reasonable to speculate that this activity might alter nuclear architecture 
and be important for their biological function. The ability to study changes in nuclear 
organization has rccently become more accessible through the development of techniques 
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such as Hi-C (Lieberman-Aiden et al., 2009), and it will be interesting to determine whether 
the major role of some transcription factors is to re-organize the architecture of the nucleus. 
Selective advantage model to explain widespread binding 
The relationship between the feed-forward network motif and the evolution of new 
transcriptional regulatory networks is another theoretical model for understanding a potential 
biological role for genome-wide binding. Feed-forward regulation is the dominant motif for 
regulating complex biological pathways, with the ability to temporally regulate the 
expression of its targets while retaining the ability to rapidly cease target expression (Cordero 
and Hogeweg, 2006; Lee et aL, 2002; Shen-Orr et al., 2002). Feed fOlward circuits have 
been found to occur repeatedly in S. cerevisiae, and have via convergent evolution, 
suggesting their widespread utility (Conant and Wagner, 2003). 
Genome-wide transcription factor binding and feed-forward mechanisms might have 
led to the evolution of distinct regulatory networks from a common network, a theory that 
can be understood using MyoD as an example. MyoD directly binds and regulates genes 
expressed throughout the program of skeletal myogenesis. At many targets, binding alone is 
not sufficient for transcriptional activation, but instead requires cooperation with factors that 
MyoD also regulates, thereby achieving temporal patterning through the feed-forward circuit. 
The evolution of a feed-forward circuit can be easily understood as the refinement of an 
initial single-input motif (Fig 4.2). For example, a primitive MyoD-like factor might have 
initially activated all the genes necessary for a primitive muscle cell phenotype, providing 
some selective advantage for this initial event. Subsequently, feed-forward regulation could 
be superimposed on the single-input motif to gradually improve and regulate the final output. 
One prediction of this model is that factors with the potential to regulate complex 
transcriptional programs would bind throughout the genome because mutations in factors that 
sample a large portion of the genome would have the highest probability of generating a new 
network by changing the expression of large numbers of genes. Again using MyoD as an 
example, MyoD binds within a regulatory distance of more than one-half of all genes (Cao et 
aL,2010). Altering the activation potential of MyoD through a translocation or mutation 
94 
could drastically alter genome-wide transcription and potentially generate a novel complex 
phenotype from a single genetic event. In this model, genome-wide binding of a subset of 
transcription factors might reflect an evolutionary advantage rather than a cell-type specific 
function. 
Comparing the findings from genome-wide transcription factor binding studies 
supports two general types of transcription factor binding. In some studies, the transcription 
factors tend to bind in the neighborhood of that they regulate, whereas in others the 
factors bind throughout the genome and relatively equivalently at both regulated and 
apparently non-regulated genes. A major caveat in suggesting that these might represent 
different biological sU'ategies is the problem inherent to comparing results from different 
studies. Differences in sample preparation, data acquisition, and data processing can result in 
dramatically different conclusions that do not directly reflect the biology of the factors 
studied. Having acknowledged this important caveat, some factors appear to have binding 
profiles that reflect their regulatory network. For these factors it should be possible to infer 
their function based on knowledge of their binding sites, and, ultimately, it might be possible 
to compute their regulatory networks directly from knowledge of the organism's DNA 
sequence. The binding profiles of other factors appear much too dispersed across the 
genome to accurately correlate binding with regional transcription. For these factors, it 
might be impossible to infer their regulatory networks from DNA sequence, or even from 
knowledge of where they are physically bound. It remains to be determined whether these 
genome-wide binding events have one or more biological functions that are distinct from 
regulating regional transcription. Although speculative, this raises the intriguing possibility 
that the majority of binding events of some transcription factors might not be the direct 
regulation of transcription, but rather a currently unrecognized role in genome-wide biology. 
Table 4.1. Numbers of Transcription Factor Bound Sites from Select ChiP-chip and 
ChlP·Seq Experiments 
Transcription Species Factor 
Ste12 S. cerevisiae 
Pha-4 C. efegans 
Twist D. 
mefanogaster 
Twist D. 
mefanogaster 
NRSF human 
Tal1 mouse 
Taf1 human 
PXR mouse 
CaRF mouse 
STAT1 human 
GATA1 mouse 
Technique 
ChiP-chip 
ChiP-Seq 
ChiP-chip 
ChiP-chip 
ChiP-Seq 
ChiP-Seq 
ChiP-Seq 
ChiP-Seq 
ChiP-Seq 
ChiP-Seq 
ChiP-Seq 
Reported # of 
Bound Sites 
65/5r 
4350/4808b 
2096 
3000 
1946 
2994 
6315 
3812/6446c 
176 
11004/41582d 
15360 
Ref 
Zeitlinger, 2003 
Zhong,2010 
Sandmann, 
2006 
Zeitlinger, 2007 
Johnson,2007 
Kassouf, 2010 
Palii,2010 
Cui, 2010 
Pfenning, 2010 
Robertson, 
2007 
Cheng, 2009 
CTCF human ChiP-chip 13804 Ganapathi, 
2010 
CTCF human ChiP-Seq 20262 Kim, 2007 
CTCF mouse ChiP-Seq 39609 Chen, 2008 
MyoD mouse ChiP-Seq 25956/5926r Cao, 2010 
a: Binding sites are those specifically identified in either mating or filamentous growth 
conditions, respectively. 
b: Binding sites are in embryos, and L 1 larvae, respectively. 
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c: Binding sites are listed for basal conditions, and conditions in which a synthetic activator 
of PXR was used, respectively. 
d: Binding sites are listed for conditions of non-stimulated and interferon-y-stimulated cells, 
respectively. 
e: Binding sites are listed at two different statistical cutoffs (false discovery rates of 10-7 and 
0.018, respectively) 
(a) 
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Figure 4.1. Examples of regulatory motifs used to control transcription. A variety of 
mechanisms, or regulatory motifs, are used to control the expression of specific gene targets 
over unique spacial (eg. specific tissue types) and/or temporal contexts. (A) Feed forward 
regulation permits temporal control of the targets of a single transcription factor. A 
transcription factor, represented by the grey circle, binds to multiple DNA targets (blue and 
black targets), but only activates one of them (top half of Figure 4.1a). The gene target that it 
activates (red circle) can then also bind to one of the same gene targets as the original factor 
(black), and together they activate transcription (bottom half of Figure 4.la) . (B) The use of 
cooperative factors permits transcription factors to be expressed widely, but discriminately 
activate gene targets. A single transcription factor, again represented by the grey circle, 
binds to mUltiple gene targets, activating one (the blue line) consistently, regardless of the 
cellular context (either tissue type or time) . Other targets that it binds to in both cases (black 
and red targets), are activated only if they are also bound by another factor (compare 
activation of black and red targets between left and right side of Figure 4.1 b), expressed 
specifically in that cellular condition. 
97 
A 
B B' 
:I,SCL ~:/r'S 
~ 
c 
~ Related / Transcription (\ Factors 
'\ -L::.... Activated Gene Target 
---!:! Non-activated 
'\ Binding Target 
----+ Factor Binding 
Figure 4.2. Genome-wide binding and the evolution of transcriptional networks. The 
ability of certain transcription factors to bind widely throughout the genome could permit the 
evolution of new transcriptional regulatory networks in a relatively limited number of events. 
This could mean that genome-wide binding might actually serve an evolutionary advantage 
in cells, permitting them to more easily acquire new networks and phenotypes, as a result of 
the different genes involved in those networks. (A) Schematic representation of a 
transcription factor that binds to many sites throughout the genome and regulates 
transcription at a subset of these sites in a single input motif, in which it alone regulates the 
expression of the targets at which it binds. (A') Duplication and sequence divergence of this 
factor can give rise to a family member with similar DNA binding characteristics but 
transcriptional regulation of an overlapping yet distinct set of genes. The more promiscuous 
the binding of factor A and A', the greater the subset of genes they have the potential to 
influence and the greater potential for target diversity between A and A'. Therefore, 
changing from A to A' could lead to the generation of a new complex program by a single 
factor modification. (B and B') If the cellular phenotype conferred by the set of genes 
regulated in A and A' have some selective advantage, then the single input motif can be 
refined by the gradual super-imposition ofa feed-forward motif to achieve temporal 
regulation and more robust kinetics. (C) It is also possible for feed-forward motifs to 
degenerate into simple cascades of regulated genes over time if subsequent mutations in the 
original factor limit the set of genes that can be directly bound, further separating the two 
networks that originally came from a common progenitor. 
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Chapter 5: Discussion 
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miR-206 in rhabdomyosarcomas 
The finding that miR-206 increases in responsc to the effects that MyoD-E, RUNXI, 
RP58 all have on RMS suggests that it is a key point of integration for the process of 
differentiation. It is somewhat surprising to consider that a single mieroRNA could be of 
such crucial importance, but there are still many unanswered questions about the function of 
miR-206 and the finer details of its effects. miR-206 is highly similar to the microRNA miR-
1, which also leads to differentiation in myogenic cells, but they have different expression 
patterns in organisms and apparent differences in regulation as well (Callis et ai., 2008). The 
miR-20611 family is highly conserved, with diverse organisms down to zebrafish having an 
identical mature miR-206 sequence to that of human, offering further credence to the idea 
that it is a crucial part of the myogenic program. 
It had previously been established that MyoD controls miR-206 expression, and I 
have now expanded that work to demonstrate an inhibitory role for both the bHLH protein 
MSC as well as an activating role for RUNXI. The expression ofRP58 also leads to an 
increase in miR-206 levels, but there is no evidence for the effect being direct, suggesting 
that it likely is affecting miR-206 indirectly by its ability to alter bHLH dimer balance. Other 
groups have provided evidence that factors such as YYI and API also affect miR-206 
expression (Song and Wang, 2009), further expanding the list of factors that appear to 
regulate its expression. IfmiR-206 expression is as crucial to myogenesis as its effects on 
RMS implies, having it be regulated by so many factors may be an evolutionary advantage, 
allowing it to respond in a carefully modulated fashion to a variety of effects on the cell. It is 
also worth noting that the evidence that YYl negatively regulates miR-206 may also explain 
the aforementioned ability of the NF-KB/YY-1/miR-29b circuit to differentiate RMS. In my 
experiments, I could find no evidence that the forced protein dimer increased miR-29b levels, 
and it is possible that the effects on YYl by the other groups actually led to a derepression of 
miR-206 expression, and an increase in miR-206 expression was the causative factor for the 
observed differentiation. 
It is still unclear at this point what the precise mechanism is by which increased miR-
206 expression leads to differentiation. It has been shown to directly and indirectly 
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downregulate a variety of targets (eg. a specific D ~A polymerase subunit, MSC) in 
myogenic cells that make logical sense given its but it is unknown if there is a single 
crucial target or if the effects ofmiR-206 are due to a cumulative effect on a variety of 
factors. Certainly, the finding that NOTCH3, and the Notch ligand DLL3, are downregulated 
in response to the lentiviral expression ofmiR-206 is of interest and warrants further study. 
NOTCH3 has been identified as a direct miR-206 target (Song et aI., 2009), but the effect of 
specific interference with ~OTCH3 in RMS or other myogenic cells is unknown. It is 
possible that interference with the inhibitory ~otch pathway in the proper manner may result 
in RMS differentiation, but it also is possible that downregulation of the Notch pathway is 
permissive, but not sufficient, for differentiation in the cells. If so, it would be interesting to 
determine if Notch downregulation could potentiate manipUlations like MSC siRNA and 
result in successful differentiation of the cells. 
Another outstanding puzzle about the effect ofmiR-206 in RMS, as well as its role in 
myogenesis in general, is the relationship between it and miR-133b. In both my experiments, 
as well as previously published data, miR-206 and miR-133b appear to have opposing effects 
- one pushing differentiation, and the other interfering with that process, respectively. It 
appears paradoxical then, that they are processed from the same primary transcript and, in my 
experiments, both increase sharply in response to RMS differentiation. Given the results of 
my transient transfections of each microRNA into RD cells, it is clear that the pro-
differentiation effects are specific to miR-206, as would be expected from all prior data. 
While it is not necessarily of direct bearing on RMS, this system might offer a tractable 
manner to begin to address the question of how miR-206 and -133b interact and the relative 
strength of their effects. It is possible that, while increased levels ofmiR-206 lead to 
differentiation, that its effect is actually being diminished or modulated by the increased 
levels ofmiR-133b. If so, it raises the possibility that interference with miR-133b activity, 
expression, or processing might be sufficient to cause RMS differentiation; my microRNA 
Northern blots clearly demonstrate that miR-206 is being expressed at easily detectable levels 
in 'normal' RD cells and, unopposed, it may be sufficient to differentiate the cells. 
RUNXI and RP58 in rhabdomyosarcomas and myogenesis 
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My findings with RUNX1 and RP58 place both factors downstream of MyoD in 
human cells, and as positive regulators of myogenesis, but there are still many unanswered 
questions about the specifics of their roles and effects. The findings with RUNX 1 in Chapter 
2 suggest that it functions directly at important downstream targets of MyoD, including miR-
206 and RP58, to increase their expression. The arrays results suggest it may also function in 
a similar manner at the transcription factors MYOG and MEF2C and MEF2D as well, making 
it have a remarkably extensive effect on the later stages of myogenesis that are affected by 
such factors. 
The ChIP-Seq data in Chapter 3 also points to RUNX 1 playing an important role in 
differentiated myotubes, but in that analysis its binding site is found to be associated with 
MyoD binding sites found only in differentiated human myotubes. While the motif analysis 
does not explain causation, it could mean that RUNX1 is actually responsible for helping to 
recruit MyoD to bind at some subset of locations throughout the genome. Given the effect 
that expression of RUNX1 has on Rl\1S, it would suggest that this subset of sites is of critical 
functional importance to myogenesis. It is possible, however, that there is another reason 
that MyoD cannot bind at those locations, and that the locations it is not binding at are ones 
that later require RUNXI binding for activation. ChIP experiments for MyoD in RUNXl-
differentiated cells would be able to address that question, determining if RUNXI expression 
shifts MyoD to be bound at those sites. The effect that RUNXI has on sites where MyoD is 
already bound (such as miR-206 and RP58) will also need to be investigated, to further 
understand how it assists MyoD in activating some of its targets. 
RP58 has been described as directly downregulating Jd2 and Jd3, a role that ties in 
perfectly with our model of a tipping point in RMS. By downregulating those two inhibitory 
factors, RP58 could enhance the association of productive MyoD:E-protein dimers, and 
increase myogenic activity in RMS. Indeed, the qPCR data after expression of RP58 
suggests that JD downregulation is occurring in the RD cells. However, our ChIP-Seq MyoD 
data in murine cells also suggests another role for RP58 binding. The RP58 motif is 
associated with MyoD peaks that decrease during the process of differentiation a decrease 
in occupancy that is associated with genes that decrease in expression. Since RP58 has a 
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binding motif that is a variant of a type of E-box (ACATCTG), this would suggest that RP58 
binding ofE-boxes might even be directly interfering with or displacing bound MyoD. 
Given that RP58 is clearly a downstream target ofMyoD according to both my findings and 
those of other groups (Yokoyama et aI., 2009), this would suggest that MyoD induces the 
expression offactors that then interfere with MyoD binding itself at some subset of targets to 
cause target downregulation. Certainly, this effect and the possibility suggested by my arrays 
that RP58 downregulates both positive cell cycle regulators and the HESIHEYfamily 
warrants further study of its direct effects, but my attempts to ChIP it have all failed. Two 
antibodies to RP58 as well as an antibody against a tagged version of the protein have all 
failed to enrich RP58 at either of the JD genes, and it appears that other reagents or 
approaches will be necessary to further investigate the role and action of RP58 in 
myogeneSlS. 
Genome-wide binding of bHLH factors in rhabdomyosarcomas 
The data reported in Chapter 3 that MyoD binds widely throughout the genome of RD 
cells, and at a comparable number of sites to MyoD in primalY human cells, is in agreement 
with our previous findings that the DNA binding capabilities of MyoD are not compromised 
in JL\1S. The finding that is significantly more surprising is the widespread nature of MSC 
binding. While it is unknown how many genes MSC regulates, the results from the knockout 
mice make it reasonable to speculate that it would be a relatively small set of genes, and 
certainly smaller than the set of MyoD-controlled genes. Granted, as the ChIP-Seq with 
MyoD has demonstrated, and as discussed in Chapter 4, DNA binding does not have to 
correlate with function at an immediately adjacent target. Even given that, it is startling to 
think that a factor that affects some subset of MyoD activity, and that is not the only bHLH 
myogenic inhibitor that has been described, is bound at a comparable number of locations as 
MyoD throughout the genome. 
Future work will need to more carefully define the targets ofMSC activity and 
compare that to the ChIP-Seq data, to determine if there are defining or distinguishing 
characteristics to targets that would explain how MSC and MyoD coordinate their activities. 
The finding that MSC-specific peaks are found at E-boxes with a sequence that would be 
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consistent with a homodimer binding (CCAGCTGG) could be of particular functional 
significance. In vitro experiments and the mass spectromctry data make it clear that MSC 
associates with E-proteins in complexes, but its relative affinity for heterodimerization versus 
homodimerization, if MSC homodimerization is even something that occurs in vivo, is 
completely unknown. Experiments including ChIPs could begin to shed light not only on 
that question, but on the question of whether widespread binding at and near MyoD-bound 
sites is a common occurrcnce for any type of transcription factor that negatively regulates 
myogenesis, or something more unique to MSC or bHLH inhibitors specifically. 
One ofthe most unexpected findings from the MyoD ChIP-Seq in RD cells is the 
finding that the proportion of 'GC' versus 'GG' E-boxes is different between RDs and 
primary human myotubes. The two sequences are the most highly bound E-boxes by MyoD, 
but ChIP-Seq with other cell types in our lab has demonstratcd that the 'GG' E-box is more 
MyoD specific, while the 'GC' E-box is bound by other bHLH factors as well. The 
functional significance of this E-box shift is therefore unclear but, as mentioned in Chapter 3, 
the single nucleotide difference in the E-boxes appears to be on the side occupied by the E-
protein. Given the difference in expression levels ofHEB and E2-2 that I see between 
myotubes and RD cells, the E-box sequence preference of each E-protein when 
heterodimerized with MyoD needs to be determined - cxperimcnts that can be accomplished 
through EMSA. If onc of the E-proteins that is noticeably underrepresented in RD cells is 
found to have a strong GC E-box preference, this may explain the observed difference in 
occupied E-boxes. In that case, the effect on RD cells of cxpression of that specific E-protein 
will need to be investigated to detennine if it affects the state of myogenesis in the cells or 
leads to differentiation. 
The arrested state of rhabdomyosarcomas 
MyoD is a potent driver of the myogenic fate, and possesses a remarkable ability to 
drive a variety of cells to become tenninally differentiated myotubes. The process of 
myogenesis has been described as being 'all-or-nothing' in nature, referring to the fact that 
when a cell undergoes the process of myogenesis, it proceeds fully to the state of myotube, 
without clearly defined transitional states or stages along the way. But the fact that such a 
state has not been clearly defined or described does not necessarily imply that it does not 
exist. 
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The data described herein, both from myself and others from our group, suggests that 
rhabdomyosarcoma cells may represent or be trapped in just such a transitional state. While 
retaining a morphology more closely reminiscent ofmyoblasts than myotubes, and 
continuing to proliferate rapidly, RMS cells possess many characteristics of myogenic cells 
that are beginning to differentiate. From expressing later myogenie genes and factors such as 
MYOG and miR-206, to having a genome-wide binding pattern of MyoD that more closely 
resembles myotubes than myoblasts, to the multiple means that we have found are capable of 
driving differentiation in the cells, RMS appear to be on the brink of completing myogenesis 
even before experimental manipulations. The fact that the means I have found that 
differentiate the cells RUNXl, RP58, and miR-206, in addition to the forced MyoD~E­
protein dimer all appear to play some role in the normal process of myogenesis implies that 
the regulatory relationships that exist in normal myogenesis are relatively preserved in RMS. 
Studies of RMS biology then, offer the interesting benefit of not only understanding 
the biology of a type of tumor, but providing information about normal myogenesis at a stage 
that has generally been inaccessible in studies of normal myogenic cells. Experiments with 
most myogenic cell culture models or animal models tend to compare cells when they are as 
undifferentiated as is possible to myotubes at various time points. Isolating a population of 
cells that are, as a whole, at the same point in between those two ends is technically difficult, 
and can suffer from problems with inconsistent cell density or passaging in culture models. 
RMS offer the possibility of studying that otherwise problematic point in the process of 
differentiation with some consistency. 
Our current model for the state of RMS (Figure 1.1) suggests that, as a result of the 
cells being on the verge of differentiation at a 'tipping point' - and since multiple factors 
impact on their state, multiple points of manipulation exist that can result in differentiation. 
This effect should be possible not only by enhancing the activity of MyoD and myogenesis in 
general, but by interfering with the activity of the inhibitory factors as well. The factors that 
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I have found all appear to function by assisting, or functioning as a downstream effector, of 
MyoD, and it would be of great interest to explore what other inhibitors could be depleted or 
inhibited to drive differentiation. We have previously reported that siRNA-mediated 
knockdown of MSC was not sufficient to drive differentiation, but that expression of a DNA-
binding dominant negative MSC resulted in the formation of myotubes in RD cells (Lee et 
a1., 2011; Yang et a1., 2009). Experiments by other groups that have affected myogenic 
inhibitors and caused RMS differentiation have used shRNA and dominant negative 
approaches (Lee et aI., 2011; Sang et aI., 2008), and the technical details of these experiments 
may be key to their success or failure. Certainly, given the widespread binding ofMSC 
throughout the genome described in Chapter 3, transient transfection of siRNA constructs 
may simply be inadequate for depleting the DNA-bound MSC at sufficient levels to allow the 
myogenic balance to tip and differentiation to proceed. Approaches that have a longer-term 
effect and/or greater efficacy may be crucial for success when attempting to interfere with 
other myogenic inhibitors of interest in future experiments. 
As mentioned above, inhibitory factors that affect the 'tipping point' in RMS include 
KMTlA and lIES 1. My findings with RP58 suggest that the ID proteins also playa role on 
the side of inhibition, and we have already described E2A-2/5 and MSC as doing so. It is 
also possible that the PAX genes, lying genetically upstream of the MRFs, may function as 
inhibitors in this model and these tumors when existing as the P AX-FKHR fusion. My work 
expands the factors that act in a positive fashion on the process of myogenesis in this model 
to include RUNXl, RP58, and miR-206. Future work will need to further explore the 
relationship between the positive factors and the inhibitory ones, and especially the 
molecular mechanisms that are responsible for the downregulation and inhibition of the 
inhibitory factors that lock in the process of terminal differentiation. Certainly, the fact that 
multiple means exist that all cause RMS differentiation and withdrawal from the cell cycle is 
encouraging for the possibility to find a druggable target that could be used to leverage a 
novel differentiation-based therapy for these tumors. 
Finally, thc model of ReYiS as a solid tumor that represents an arrested state of 
development and possesses a 'tipping point' that can be manipulated may be more broadly 
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applicable than to just these specific tumors. bHLH factors control differentiation in other 
cell types, such as neurons, and it is possible that other pediatric tumors may be trapped in an 
analogous state to RIvlS even those tumors that come from cell types where bHLH factors 
are not in a controlling role. Future experiments examining tumors other than 
rhabdomyosarcoma will be needed to determine if the lessons from these cells can be of use 
in other systems. 
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